

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 February 2002 (28.02.2002)

PCT

(10) International Publication Number
WO 02/16657 A1

- (51) International Patent Classification⁷: C12Q 3/00, 1/68, 33/567, C12P 21/04, C12N 15/00, 5/00, C07H 21/04
- (74) Agent: FIELD, Bret, E.; Bozicevic, Field & Francis, LLP, Suite 200, 200 Middlefield Road, Menlo Park, CA 94025 (US).
- (21) International Application Number: PCT/US01/25861
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 17 August 2001 (17.08.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/227,865 24 August 2000 (24.08.2000) US
60/230,174 1 September 2000 (01.09.2000) US
60/238,345 5 October 2000 (05.10.2000) US
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): SIERRA SCIENCES, INC. [US/US]; Suite 130, 250 South Rock Boulevard, Reno, NV 89502 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): ANDREWS, William, H. [US/US]; 3430 Rosalinda Drive, Reno, NV 89503 (US). FOSTER, Christopher, A. [US/US]; 2806 Panay Court, Carmichael, CA 95608 (US). FRASER, Stephanie [US/US]; 1011 Tyler Way, Sparks, NV 89431 (US). MOHAMMADPOUR, Hamid [US/US]; 4748 Cedar Hill Lane, Reno, NV 89509 (US).
- Published:**
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 02/16657 A1

(54) Title: METHODS AND COMPOSITIONS FOR MODULATING TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION

(57) Abstract: Methods and compositions are provided for modulating, and generally upregulating, the expression of telomerase reverse transcriptase (TERT) by blocking repression of TERT transcription, e.g., by inhibiting binding of repressor factor to a Site C repressor binding site located in the TERT minimal promoter. The subject methods and compositions find use in a variety of different applications, including the immortalization of cells, the production of reagents for use in life science research, therapeutic applications; therapeutic agent screening applications; and the like. In further describing the subject invention, the method and compositions of the invention are described first in greater detail, followed by a review of the various applications in which the subject invention finds use.

5

METHODS AND COMPOSITIONS FOR MODULATING TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION

CROSS-REFERENCE TO RELATED APPLICATIONS

10

Pursuant to 35 U.S.C. § 119 (e), this application claims priority to the filing dates of the United States Provisional Patent Application Serial Nos. 60/227,865 filed August 24, 2000; 60/230,174 filed September 1, 2000 and 60/238,345 filed October 5, 2000, the disclosures of which are herein

15 incorporated by reference.

INTRODUCTION

Field of the Invention

20

The field of this invention is the telomerase reverse transcriptase gene, specifically the regulation of the expression thereof.

Background of the Invention

25

Telomeres, which define the ends of chromosomes, consist of short, tandemly repeated DNA sequences loosely conserved in eukaryotes. Human telomeres consist of many kilobases of (TTAGGG)_n together with various associated proteins. Small amounts of these terminal sequences or telomeric DNA are lost from the tips of the chromosomes during S phase because of incomplete DNA replication. Many human cells progressively lose terminal sequence with cell division, a loss that correlates with the apparent absence of telomerase in these cells. The resulting telomeric shortening has been

30 demonstrated to limit cellular lifespan.

Telomerase is a ribonucleoprotein that synthesizes telomeric DNA. Human telomerase is made up of two components: (1) an essential structural RNA (TER) (where the human component is referred to in the art as hTER);

and (2) a catalytic protein (telomerase reverse transcriptase or TERT) (where the human component is referred to in the art as hTERT). Telomerase works by recognizing the 3' end of DNA, e.g., telomeres, and adding multiple telomeric repeats to its 3' end with the catalytic protein component, e.g.,

5 hTERT, which has polymerase activity, and hTER which serves as the template for nucleotide incorporation. Of these two components of the telomerase enzyme, both the catalytic protein component and the RNA template component are activity limiting components.

Because of its role in cellular senescence and immortalization, there is
10 much interest in the development of protocols and compositions for regulating expression of telomerase.

Relevant Literature

U.S. Patents of interest include: 6,093,809; 6,054,575; 6,007,989;
15 5,958,680; 5,858,777. Also of interest are WO 99/33998 and WO 99/35243. Articles of interest include: Cong et al., Hum. Mol. Genet. (1999) 8:137-142; Crowe et al., Nucleic Acids Res. (July 1, 2001) 29:2789-2794; Crowe et al., Biochim Biophys Acta (March 19, 2001) 1518:1-6; Henderson et al., Head Neck (July 2000) 22:347-354; Kim et al., Oncogene (May 10, 2001) 20:2671-
20 82; Takakura et al., Cancer Res. (1999) 59:551-7; and Yasui et al., J. Gastroenterol. (2000) 35 Suppl. 12: 111-115. See also GENBANK accession nos. AF114847 and 128893.

SUMMARY OF THE INVENTION

25 Methods and compositions are provided for modulating, and generally upregulating, the expression of telomerase reverse transcriptase (TERT) by blocking repression of TERT transcription, e.g., by inhibiting binding of repressor factor to a Site C repressor binding site located in the TERT minimal promoter, where in certain embodiments the repressor factor acts in concert
30 with one or more cofactors in binding to the Site C repressor site to inhibit the TERT transcription site. The subject methods and compositions find use in a variety of different applications, including the immortalization of cells, the production of reagents for use in life science research, therapeutic applications; therapeutic agent screening applications; and the like.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 provides the sequence of the minimal Tert Promoter referenced in the experimental section, below.

5 Figure 2 provides an annotated sequence of the pSSI20 plasmid references in the Experimental Section, below.

Figure 3 provides graphical results of the fine mapping analysis experiment reported in the Experimental Section, below.

10 DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Methods and compositions are provided for modulating, and generally upregulating, the expression of telomerase reverse transcriptase (TERT) by blocking repression of TERT transcription, e.g., by inhibiting binding of repressor factor to a Site C repressor binding site located in the TERT minimal
15 promoter, where in certain embodiments the repressor factor acts in concert with one or more cofactors in binding to the Site C repressor site to inhibit the TERT transcription site. The subject methods and compositions find use in a variety of different applications, including the immortalization of cells, the production of reagents for use in life science research, therapeutic
20 applications; therapeutic agent screening applications; and the like. In further describing the subject invention, the methods and compositions of the invention are described first in greater detail, followed by a review of the various applications in which the subject invention finds use.

25 Before the subject invention is described further, it is to be understood that the invention is not limited to the particular embodiments of the invention described below, as variations of the particular embodiments may be made and still fall within the scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing
30 particular embodiments, and is not intended to be limiting. Instead, the scope of the present invention will be established by the appended claims.

In this specification and the appended claims, the singular forms "a," "an" and "the" include plural reference unless the context clearly dictates

otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs.

5 Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range, and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may
10 independently be included in the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

15

 Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. Although any methods, devices and materials similar or equivalent to those described herein can be used in the
20 practice or testing of the invention, the preferred methods, devices and materials are now described.

METHODS

25

 As summarized above, the subject invention provides methods and compositions for modulating expression of TERT. In the subject methods, TERT expression repression is modulated by modulating the TERT expression repression activity of a Site C repressor binding site located in the TERT
30 minimal promoter, where modulating includes both increasing and decreasing the expression repressive activity of the Site C repressor binding site. As such, in certain embodiments, methods of increasing expression of TERT are provided, while in other embodiments, methods of decreasing expression of TERT are provided, where in both embodiments the modulation of expression

is accomplished by modulating the repressor activity of the Site C repressor site.

Site C Repressor Site

5

The Site C repressor site whose activity is modulated in the subject methods comprises a sequence of nucleotide residues that is bound by an E2F protein, or at least an E2F DNA binding domain of an E2F protein. E2F proteins to which the subject Site C repressor site binds include, but are not limited to: E2F-1, E2F-2, E2F-3, E2F-4, E2F-5 and E2F-6.

The target Site C repressor site typically ranges in length from about 1 base, usually at least about 5 bases and more usually at least about 15 bases, to a length of about 25 bases or longer, e.g., 50, 75 or 100, etc. In many embodiments, the length of the target Site C repressor site/domain ranges in length from about 1 to about 50 bases, usually from about 5 to about 45 bases.

In many embodiments, the target Site C site has a sequence found in a limited region of the human tert minimal promoter, where this limited region typically ranges from about -40 to about -90, usually from about -45 to about -85 and more usually from about -45 to about -80 relative to the "A" of the telomerase ATG codon.

Of particular interest in certain embodiments is a nucleic acid having a sequence found in SEQ ID NO:01 (e.g., a sequence range of at least about 2, usually at least about 5 and often at least about 10, 20, 25, 30 or more bases up to about 45 to 50 bases, where, in certain embodiments, the target Site C domain will have a sequence that is identical to a sequence of SEQ ID NO:01. SEQ ID NO:01 has the following sequence:

GGCCCCGCCCTCTCCTCGCGGCGCGAGTTTCAGGCAGCGCT (SEQ ID
NO:01)

In certain embodiments, the target Site C site includes the sequence of -69 to -57 of the human TERT minimal promoter. In other words, the sequence of the Site C site is:

GGCGCGAGTTTCA (SEQ ID NO:02).

5 In certain embodiments, the target Site C site includes the sequence of -67 to -58 of the human TERT minimal promoter. In other words, the sequence of the Site C site is:

CGCGAGTTTC (SEQ ID NO:03).

10

In certain embodiments, the target Site C site includes the sequence of -69 to -49 of the human TERT minimal promoter. In other words, the sequence of the Site C site is:

15

GGCGCGAGTTTCAGGCAGCGC (SEQ ID NO:04).


Also of interest are Site C sites that have a sequence that is substantially the same as, or identical to, the Site C repressor binding site sequences as described above, e.g., SEQ ID NOs: 01 to 04. A given
20 sequence is considered to be substantially similar to this particular sequence if it shares high sequence similarity with the above described specific sequences, e.g. at least 75% sequence identity, usually at least 90%, more usually at least 95% sequence identity with the above specific sequences. Sequence similarity is calculated based on a reference sequence, which may
25 be a subset of a larger sequence. A reference sequence will usually be at least about 18 nt long, more usually at least about 30 nt long, and may extend to the complete sequence that is being compared. Algorithms for sequence analysis are known in the art, such as BLAST, described in Altschul *et al.* (1990), *J. Mol. Biol.* 215:403-10 (using default settings, i.e. parameters $w=4$ and $T=17$). Of particular interest in certain embodiments are nucleic acids of
30 substantially the same length as the specific nucleic acid identified above, where by substantially the same length is meant that any difference in length does not exceed about 20 number %, usually does not exceed about 10 number % and more usually does not exceed about 5 number %; and have

sequence identity to this sequence of at least about 90%, usually at least about 95% and more usually at least about 99% over the entire length of the nucleic acid. Also of interest are nucleic acids that represent a modified or altered Site C site, e.g., where the site includes one or more deletions or substitutions as compared to the above specific Site C sequences, including a deletion or substitution of a portion of the Site C repressor binding site, e.g., a deletion or substitution of at least one nucleotide.

Modulating TERT Expression

The subject invention provides methods of modulating, including both enhancing and repressing, TERT expression. As such, methods of both increasing and decreasing TERT expression are provided. In many embodiments, such methods are methods of modulating the binding interaction and resultant Site C TERT expression repression activity between a Site C site in a minimal TERT promoter and a Site C repressor protein, where in many embodiments the Site C repressor protein is a protein having an E2F DNA binding domain, particularly a Site C E2F DNA binding domain. As such, included are methods of either enhancing or inhibiting binding of Site C repressor protein to a TERT minimal promoter Site C site.

As indicated above, the Site C repressor protein whose interaction with the Site C repressor site is modulated in the subject methods is a protein that binds to the Site C repressor site and, in so binding, inhibits TERT expression. In many embodiments, the Site C repressor protein is a protein that binds to the Site C site via an E2F DNA binding domain present on the repressor protein, i.e., that is part of the repressor protein. In certain embodiments, the target Site C repressor proteins are proteins that include a DNA binding domain having a sequence of residues according to the following formula, where X is any residue:



In certain embodiments, the target Site C repressor proteins are proteins that include a DNA binding domain that has an amino acid sequence that is at least homologous to the amino acid sequence of the DNA binding domain of either

E2F-1 or E2F-4. The amino acid sequence of the DNA binding domain of E2F-1 is:

GRGRHPGKGVKSPGEKSRYETSLNLTTRKFLELLSHSADGVVDLNWAAEVL
KVQKRRIYDITNVLEGIQLIA KKSKNHIQWLGSH (SEQ ID NO:05).

- 5 The amino acid sequence of the DNA binding domain of E2F-4 is:
PPGTPSRHEKSLGLLTTKFVSLLEAKDGVLDLKLAAADTLAVRQKRRIYDITN
VLEIGLIEKKSKNSIQWK GVGP (SEQ ID NO:06).

By at least homologous is meant that the target Site C repressor protein has a DNA binding domain which includes an amino acid sequence that has at least
10 20%, usually at least 25% sequence identity with at least one of the specific E2F binding domains provided above, where sequence identity for this particular purpose is measured using the BLAST compare two sequences program available on the NCBI website using default settings.

As such, in certain embodiments, target repressor proteins are E2F
15 proteins. Target E2F proteins of interest include, but are not limited to: E2F-1, E2F-2, E2F-3, E2F-4, E2F-5 and E2F-6; where in certain embodiments, E2F-6 is the target protein of interest. In yet other embodiments, the target Site C repressor protein is not an E2F protein, but is instead a protein that includes an E2F DNA binding site, as described above, or homologue thereof. In
20 certain embodiments, the target Site C repressor protein acts in concert with one or more cofactors in binding to the Site C repressor site to inhibit the TERT transcription site. For example, in certain embodiments the Site C repressor protein's repressive activity upon binding to the Site C sequence is modulated by its interaction with one or more additional cofactors, in a manner
25 analogous to the manner in which E2F's 1-5 are known to be converted from activators to repressors by binding to a cofactor from the Retinoblastoma (RB) family of proteins, including pRB, p107, or p130, as reviewed in: "The Regulation of E2F by pRB-Family proteins", N. Dyson; Genes Dev, 12, p 2245-62 (1998).

30 In modulating TERT expression, the interaction between the Site C repressor site and its repressor protein can be modified directly or indirectly. An example of direct modification of this interaction is where the binding of the repressor protein to the target sequence is modified by an agent that directly changes how the repressor protein binds to the Site C sequence, e.g., by

occupying the DNA binding site of the repressor protein, by binding to the Site C sequence thereby preventing its binding to the repressor protein, etc. An example of indirect modification is modification/modulation of the Site C repressive activity via disruption of a binding interaction between the repressor

5 protein and one or more cofactors (or further upstream in the chain of interactions, such as cofactors that interact with the Site C binding protein to make it either a repressor or activator, as described above) such that the repressive activity is modulated, by modification/alteration of the Site C DNA binding sequence such that binding to the repressor protein is modulated, etc.

10

Enhancing TERT Expression

Methods are provided for enhancing TERT expression. By enhancing TERT expression is meant that the expression level of the TERT coding

15 sequence is increased by at least about 2 fold, usually by at least about 5 fold and sometimes by at least 25, 50, 100 fold and in particular about 300 fold or higher, as compared to a control, i.e., expression from an expression system that is not subjected to the methods of the present invention. Alternatively, in cases where expression of the TERT gene is so low that it is undetectable,

20 expression of the TERT gene is considered to be enhanced if expression is increased to a level that is easily detectable.

In these methods, Site C repression of TERT expression is inhibited. By inhibited is meant that the repressive activity of the TERT Site C repressor binding site/ repressor protein interaction with respect to TERT expression is

25 decreased by a factor sufficient to at least provide for the desired enhanced level of TERT expression, as described above. Inhibition of Site C transcription repression may be accomplished in a number of ways, where representative protocols for inhibiting this TERT expression repression are now provided.

One representative method of inhibiting repression of transcription is to

30 employ double-stranded, i.e., duplex, oligonucleotide decoys for the Site C repressor protein, which bind to the Site C repressor protein and thereby prevent the Site C repressor protein binding to its target Site C site in the TERT promoter, e.g., the Site C site of the TERT minimal promoter. These duplex oligonucleotide decoys have at least that portion of the sequence of the

TERT Site C site required to bind to the Site C repressor protein and thereby prevent its binding to the Site C site. In many embodiments, the subject decoy nucleic acid molecules include a sequence of nucleotides that is the same as a sequence found in SEQ ID NOs: 01 to 04. In other embodiments, the subject
5 decoy nucleic acid molecules include a sequence of nucleotides that is substantially the same as or identical to a sequence found in SEQ ID NOs: 01 to 04; where the terms substantially the same as and identical thereto in relation to nucleic acids are defined below. In many embodiments, the length of these duplex oligonucleotide decoys ranges from about 5 to about 5000,
10 usually from about 5 to about 500 and more usually from about 10 to about 50 bases. In using such oligonucleotide decoys, the decoys are placed into the environment of the Site C site and its Site C repressor protein, resulting in de-repression of the transcription and expression of the TERT coding sequence. Oligonucleotide decoys and methods for their use and administration are
15 further described in general terms in Morishita et al., Circ Res (1998) 82 (10):1023-8. These oligonucleotide decoys generally include a TERT Site C repressor binding site recognized by the target Site C repressor protein, including the specific regions detailed above, where these particular embodiments include nucleic acid compositions of the subject invention, as
20 described in greater detail below.

Instead of the above described decoys, other agents that disrupt binding of the Site C repressor protein to the target TERT Site C repressor binding site and thereby inhibit its expression repression activity may be employed. Other agents of interest include, among other types of agents,
25 small molecules that bind to the Site C repressor protein and inhibit its binding to the Site C repressor region. Alternatively, agents that bind to the Site C sequence and inhibit its binding to the Site C repressor protein are of interest. Alternatively, agents that disrupt Site C repressor protein-protein interactions with cofactors, e.g., cofactor binding, and thereby inhibit Site C repression are
30 of interest.

Naturally occurring or synthetic small molecule compounds of interest include numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 50 and less than about 2,500 daltons. Candidate agents comprise

functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups.

The candidate agents often comprise cyclical carbon or heterocyclic structures

5 and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Such molecules may be identified, among other ways, by employing the screening
10 protocols described below. Small molecule agents of particular interest include pyrrole-imidazole polyamides, analogous to those described in Dickinson et al., Biochemistry 1999 Aug 17;38(33):10801-7. Other agents include "designer" DNA binding proteins that bind Site C (without causing repression) and prevent the Site C repressor protein from binding.

15 In yet other embodiments, expression of the Site C repressor protein is inhibited. Inhibition of Site C repressor protein expression may be accomplished using any convenient means, including administration of an agent that inhibits Site C repressor expression (e.g., antisense agents), inactivation of the Site C repressor gene, e.g., through recombinant
20 techniques, etc.

For example, where the Site C repressor protein is an E2F protein, e.g., E2F-6 or a homologue thereof, antisense molecules can be used to down-regulate expression of the target repressor protein in cells. The anti-sense reagent may be antisense oligodeoxynucleotides (ODN), particularly synthetic
25 ODN having chemical modifications from native nucleic acids, or nucleic acid constructs that express such anti-sense molecules as RNA. The antisense sequence is complementary to the mRNA of the targeted repressor protein, and inhibits expression of the targeted repressor protein. Antisense molecules inhibit gene expression through various mechanisms, e.g. by reducing the
30 amount of mRNA available for translation, through activation of RNase H, or steric hindrance. One or a combination of antisense molecules may be administered, where a combination may comprise multiple different sequences.

Antisense molecules may be produced by expression of all or a part of the target gene sequence in an appropriate vector, where the transcriptional initiation is oriented such that an antisense strand is produced as an RNA molecule. Alternatively, the antisense molecule is a synthetic oligonucleotide.

- 5 Antisense oligonucleotides will generally be at least about 7, usually at least about 12, more usually at least about 20 nucleotides in length, and not more than about 500, usually not more than about 50, more usually not more than about 35 nucleotides in length, where the length is governed by efficiency of inhibition, specificity, including absence of cross-reactivity, and the like. It has
10 been found that short oligonucleotides, of from 7 to 8 bases in length, can be strong and selective inhibitors of gene expression (see Wagner *et al.* (1996), *Nature Biotechnol.* 14:840-844).

A specific region or regions of the endogenous sense strand mRNA sequence is chosen to be complemented by the antisense sequence.

- 15 Selection of a specific sequence for the oligonucleotide may use an empirical method, where several candidate sequences are assayed for inhibition of expression of the target gene in an *in vitro* or animal model. A combination of sequences may also be used, where several regions of the mRNA sequence are selected for antisense complementation.

- 20 Antisense oligonucleotides may be chemically synthesized by methods known in the art (see Wagner *et al.* (1993), *supra*, and Milligan *et al.*, *supra*.) Preferred oligonucleotides are chemically modified from the native phosphodiester structure, in order to increase their intracellular stability and binding affinity. A number of such modifications have been described in the
25 literature, which alter the chemistry of the backbone, sugars or heterocyclic bases.

- Among useful changes in the backbone chemistry are phosphorothioates; phosphorodithioates, where both of the non-bridging oxygens are substituted with sulfur; phosphoroamidites; alkyl phosphotriesters
30 and boranophosphates. Achiral phosphate derivatives include 3'-O'-5'-S-phosphorothioate, 3'-S-5'-O-phosphorothioate, 3'-CH₂-5'-O-phosphonate and 3'-NH-5'-O-phosphoroamidate. Peptide nucleic acids replace the entire ribose phosphodiester backbone with a peptide linkage. Sugar modifications are also used to enhance stability and affinity. The α -anomer of deoxyribose may be

used, where the base is inverted with respect to the natural β -anomer. The 2'-OH of the ribose sugar may be altered to form 2'-O-methyl or 2'-O-allyl sugars, which provides resistance to degradation without comprising affinity. Modification of the heterocyclic bases must maintain proper base pairing.

5 Some useful substitutions include deoxyuridine for deoxythymidine; 5-methyl-2'-deoxycytidine and 5-bromo-2'-deoxycytidine for deoxycytidine. 5-propynyl-2'-deoxyuridine and 5-propynyl-2'-deoxycytidine have been shown to increase affinity and biological activity when substituted for deoxythymidine and deoxycytidine, respectively.

10 As an alternative to anti-sense inhibitors, catalytic nucleic acid compounds, e.g. ribozymes, anti-sense conjugates, etc. may be used to inhibit gene expression. Ribozymes may be synthesized *in vitro* and administered to the patient, or may be encoded on an expression vector, from which the ribozyme is synthesized in the targeted cell (for example, see International
15 patent application WO 9523225, and Beigelman *et al.* (1995), *Nucl. Acids Res.* 23:4434-42). Examples of oligonucleotides with catalytic activity are described in WO 9506764. Conjugates of anti-sense ODN with a metal complex, e.g. terpyridylCu(II), capable of mediating mRNA hydrolysis are described in Bashkin *et al.* (1995), *Appl. Biochem. Biotechnol.* 54:43-56.

20 In another embodiment, the Site C repressor protein gene is inactivated so that it no longer expresses a functional repressor protein. By inactivated is meant that the Site C repressor gene, e.g., coding sequence and/or regulatory elements thereof, is genetically modified so that it no longer expresses functional repressor protein. The alteration or mutation may take a number of
25 different forms, e.g., through deletion of one or more nucleotide residues in the repressor region, through exchange of one or more nucleotide residues in the repressor region, and the like. One means of making such alterations in the coding sequence is by homologous recombination. Methods for generating targeted gene modifications through homologous recombination are known in
30 the art, including those described in: U.S. Patent Nos. 6,074,853; 5,998,209; 5,998,144; 5,948,653; 5,925,544; 5,830,698; 5,780,296; 5,776,744; 5,721,367; 5,614,396; 5,612,205; the disclosures of which are herein incorporated by reference.

The above described methods of enhancing TERT expression find use in a number of different applications. In many applications, the subject methods and compositions are employed to enhance TERT expression in a cell that endogenously comprises a TERT gene, e.g. for enhancing expression of hTERT in a normal human cell in which TERT expression is repressed. The target cell of these applications is, in many instances, a normal cell, e.g. a somatic cell. Expression of the TERT gene is considered to be enhanced if, consistent with the above description, expression is increased by at least about 2 fold, usually at least about 5 fold and often 25, 50, 100 fold, 300 fold or higher, as compared to a control, e.g., an otherwise identical cell not subjected to the subject methods, or becomes detectable from an initially undetectable state, as described above.

A more specific application in which the subject methods find use is to increase the proliferative capacity of a cell. The term "proliferative capacity" as used herein refers to the number of divisions that a cell can undergo, and preferably to the ability of the target cell to continue to divide where the daughter cells of such divisions are not transformed, i.e., they maintain normal response to growth and cell cycle regulation. The subject methods typically result in an increase in proliferative capacity of at least about 1.2 - 2 fold, usually at least about 5 fold and often at least about 10, 20, 50 fold or even higher, compared to a control. As such, yet another more specific application in which the subject methods find use is in the delay of the occurrence of cellular senescence. By practicing the subject methods, the onset of cellular senescence may be delayed by a factor of at least about 1.2 - 2 fold, usually at least about 5 fold and often at least about 10, 20, 50 fold or even higher, compared to a control.

Methods of Inhibiting TERT Expression

As mentioned above, also provided are methods for inhibiting TERT expression, e.g., by enhancing Site C repression of TERT expression and thereby inhibiting TERT expression. In such methods, the amount and/or activity of the Site C repressor protein is increased so as to enhance Site C repressor mediated repression of TERT expression. A variety of different

protocols may be employed to achieve this result, including administration of an effective amount of the Site C repressor protein or analog/mimetic thereof, an agent that enhances expression of Site C repressor protein or an agent that enhances the activity of the Site C repressor protein.

5 As such, the nucleic acid compositions that encode the Site C repressor protein find use in situations where one wishes to enhance the activity of the repressor protein in a host. The repressor protein genes, gene fragments, or the encoded proteins or protein fragments are useful in gene therapy to treat disorders in which inhibition of TERT expression is desired, including those
10 applications described in greater detail below. Expression vectors may be used to introduce the gene into a cell. Such vectors generally have convenient restriction sites located near the promoter sequence to provide for the insertion of nucleic acid sequences. Transcription cassettes may be prepared comprising a transcription initiation region, the target gene or fragment thereof,
15 and a transcriptional termination region. The transcription cassettes may be introduced into a variety of vectors, e.g. plasmid; retrovirus, e.g. lentivirus; adenovirus; and the like, where the vectors are able to transiently or stably be maintained in the cells, usually for a period of at least about one day, more usually for a period of at least about several days to several weeks.

20 The gene or protein may be introduced into tissues or host cells by any number of routes, including viral infection, microinjection, or fusion of vesicles. Jet injection may also be used for intramuscular administration, as described by Furth et al. (1992), Anal Biochem 205:365-368. The DNA may be coated onto gold microparticles, and delivered intradermally by a particle
25 bombardment device, or "gene gun" as described in the literature (see, for example, Tang et al. (1992), Nature 356:152-154), where gold microprojectiles are coated with the DNA, then bombarded into skin cells.

Therapeutic Applications of TERT Expression Modulation

30 The methods find use in a variety of therapeutic applications in which it is desired to modulate, e.g., increase or decrease, TERT expression in a target cell or collection of cells, where the collection of cells may be a whole animal or portion thereof, e.g., tissue, organ, etc. As such, the target cell(s)

may be a host animal or portion thereof, or may be a therapeutic cell (or cells) which is to be introduced into a multicellular organism, e.g., a cell employed in gene therapy. In such methods, an effective amount of an active agent that modulates TERT expression, e.g., enhances or decreases TERT expression
5 as desired, is administered to the target cell or cells, e.g., by contacting the cells with the agent, by administering the agent to the animal, etc. By effective amount is meant a dosage sufficient to modulate TERT expression in the target cell(s), as desired.

In the subject methods, the active agent(s) may be administered to the
10 targeted cells using any convenient means capable of resulting in the desired enhancement of TERT expression. Thus, the agent can be incorporated into a variety of formulations for therapeutic administration. More particularly, the agents of the present invention can be formulated into pharmaceutical compositions by combination with appropriate, pharmaceutically acceptable
15 carriers or diluents, and may be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments (e.g., skin creams), solutions, suppositories, injections, inhalants and aerosols. As such, administration of the agents can be achieved in various ways, including oral, buccal, rectal, parenteral, intraperitoneal,
20 intradermal, transdermal, intracheal, etc., administration.

In pharmaceutical dosage forms, the agents may be administered in the form of their pharmaceutically acceptable salts, or they may also be used alone or in appropriate association, as well as in combination, with other pharmaceutically active compounds. The following methods and excipients are
25 merely exemplary and are in no way limiting.

For oral preparations, the agents can be used alone or in combination with appropriate additives to make tablets, powders, granules or capsules, for example, with conventional additives, such as lactose, mannitol, corn starch or potato starch; with binders, such as crystalline cellulose, cellulose derivatives,
30 acacia, corn starch or gelatins; with disintegrators, such as corn starch, potato starch or sodium carboxymethylcellulose; with lubricants, such as talc or magnesium stearate; and if desired, with diluents, buffering agents, moistening agents, preservatives and flavoring agents.

The agents can be formulated into preparations for injection by dissolving, suspending or emulsifying them in an aqueous or nonaqueous solvent, such as vegetable or other similar oils, synthetic aliphatic acid glycerides, esters of higher aliphatic acids or propylene glycol; and if desired, with conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives.

The agents can be utilized in aerosol formulation to be administered via inhalation. The compounds of the present invention can be formulated into pressurized acceptable propellants such as dichlorodifluoromethane, propane, nitrogen and the like.

Furthermore, the agents can be made into suppositories by mixing with a variety of bases such as emulsifying bases or water-soluble bases. The compounds of the present invention can be administered rectally via a suppository. The suppository can include vehicles such as cocoa butter, carbowaxes and polyethylene glycols, which melt at body temperature, yet are solidified at room temperature.

Unit dosage forms for oral or rectal administration such as syrups, elixirs, and suspensions may be provided wherein each dosage unit, for example, teaspoonful, tablespoonful, tablet or suppository, contains a predetermined amount of the composition containing one or more inhibitors. Similarly, unit dosage forms for injection or intravenous administration may comprise the inhibitor(s) in a composition as a solution in sterile water, normal saline or another pharmaceutically acceptable carrier.

The term "unit dosage form," as used herein, refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of compounds of the present invention calculated in an amount sufficient to produce the desired effect in association with a pharmaceutically acceptable diluent, carrier or vehicle. The specifications for the novel unit dosage forms of the present invention depend on the particular compound employed and the effect to be achieved, and the pharmacodynamics associated with each compound in the host.

The pharmaceutically acceptable excipients, such as vehicles, adjuvants, carriers or diluents, are readily available to the public. Moreover, pharmaceutically acceptable auxiliary substances, such as pH adjusting and

buffering agents, tonicity adjusting agents, stabilizers, wetting agents and the like, are readily available to the public.

Where the agent is a polypeptide, polynucleotide, analog or mimetic thereof, e.g. oligonucleotide decoy, it may be introduced into tissues or host
5 cells by any number of routes, including viral infection, microinjection, or fusion of vesicles. Jet injection may also be used for intramuscular administration, as described by Furth *et al.* (1992), *Anal Biochem* 205:365-368. The DNA may be coated onto gold microparticles, and delivered intradermally by a particle bombardment device, or "gene gun" as described in the literature (see, for
10 example, Tang *et al.* (1992), *Nature* 356:152-154), where gold microprojectiles are coated with the DNA, then bombarded into skin cells. For nucleic acid therapeutic agents, a number of different delivery vehicles find use, including viral and non-viral vector systems, as are known in the art.

Those of skill in the art will readily appreciate that dose levels can vary
15 as a function of the specific compound, the nature of the delivery vehicle, and the like. Preferred dosages for a given compound are readily determinable by those of skill in the art by a variety of means.

The subject methods find use in the treatment of a variety of different conditions in which the enhancement of TERT expression in the host is
20 desired. By treatment is meant that at least an amelioration of the symptoms associated with the condition afflicting the host is achieved, where amelioration is used in a broad sense to refer to at least a reduction in the magnitude of a parameter, e.g. symptom (such as inflammation), associated with the condition being treated. As such, treatment also includes situations where the
25 pathological condition, or at least symptoms associated therewith, are completely inhibited, e.g. prevented from happening, or stopped, e.g. terminated, such that the host no longer suffers from the condition, or at least the symptoms that characterize the condition.

A variety of hosts are treatable according to the subject methods.
30 Generally such hosts are "mammals" or "mammalian," where these terms are used broadly to describe organisms which are within the class mammalia, including the orders carnivore (e.g., dogs and cats), rodentia (e.g., mice, guinea pigs, and rats), and primates (e.g., humans, chimpanzees, and monkeys). In many embodiments, the hosts will be humans.

As indicated above, the subject invention provides methods of treating disease conditions resulting from a lack of TERT expression and methods of treating disease conditions resulting from unwanted TERT expression.

Representative disease conditions for each category are now described in
5 greater detail separately.

Treatment of Disease Conditions by Increasing TERT Expression

10 One representative disease condition that may be treated according to the subject invention is Progeria, or Hutchinson-Gilford syndrome. This condition is a disease of shortened telomeres for which no known cure exists. It afflicts children, who seldom live past their early twenties. In many ways progeria parallels aging itself. However, these children are born with short
15 telomeres. Their telomeres don't shorten at a faster rate; they are just short to begin with. The subject methods can be used in such conditions to further delay natural telomeric shortening and/or increase telomeric length, thereby treating this condition.

Another specific disease condition in which the subject methods find
20 use is in immune senescence. The effectiveness of the immune system decreases with age. Part of this decline is due to fewer T-lymphocytes in the system, a result of lost replicative capacity. Many of the remaining T-lymphocytes experience loss of function as their telomeres shorten and they approach senescence. The subject methods can be employed to inhibit
25 immune senescence due to telomere loss. Because hosts with aging immune systems are at greater risk of developing pneumonia, cellulitis, influenza, and many other infections, the subject methods reduce morbidity and mortality due to infections.

The subject methods also find use in AIDS therapy. HIV, the virus that
30 causes AIDS, invades white blood cells, particularly CD4 lymphocyte cells, and causes them to reproduce high numbers of the HIV virus, ultimately killing cells. In response to the loss of immune cells (typically about a billion per day), the body produces more CD8 cells to be able to suppress infection. This rapid cell division accelerates telomere shortening, ultimately hastening

immune senescence of the CD8 cells. Anti-retroviral therapies have successfully restored the immune systems of AIDS patients, but survival depends upon the remaining fraction of the patient's aged T-cells. Once shortened, telomere length has not been naturally restored within cells. The
5 subject methods can be employed to restore this length and/or prevent further shortening. As such the subject methods can spare telomeres and is useful in conjunction with the anti-retroviral treatments currently available for HIV.

Yet another type of disease condition in which the subject methods find use is cardiovascular disease. The subject methods can be employed to
10 extend telomere length and replicative capacity of endothelial cells lining blood vessel walls (DeBono, Heart 80:110-1, 1998). Endothelial cells form the inner lining of blood vessels and divide and replace themselves in response to stress. Stresses include high blood pressure, excess cholesterol, inflammation, and flow stresses at forks in vessels. As endothelial cells age
15 and can no longer divide sufficiently to replace lost cells, areas under the endothelial layer become exposed. Exposure of the underlying vessel wall increases inflammation, the growth of smooth muscle cells, and the deposition of cholesterol. As a result, the vessel narrows and becomes scarred and irregular, which contributes to even more stress on the vessel (Cooper, Cooke
20 and Dzau, J Gerontol Biol Sci 49: 191-6, 1994). Aging endothelial cells also produce altered amounts of trophic factors (hormones that affect the activity of neighboring cells). These too contribute to increased clotting, proliferation of smooth muscle cells, invasion by white blood cells, accumulation of cholesterol, and other changes, many of which lead to plaque formation and
25 clinical cardiovascular disease (*ibid.*). By extending endothelial cell telomeres, the subject methods can be employed to combat the stresses contributing to vessel disease. Many heart attacks may be prevented if endothelial cells were enabled to continue to divide normally and better maintain cardiac vessels. The occurrence of strokes caused by the aging of brain blood vessels may
30 also be significantly reduced by employing the subject methods to help endothelial cells in the brain blood vessels to continue to divide and perform their intended function.

The subject methods also find use in skin rejuvenation. The skin is the first line of defense of the immune system and shows the most visible signs of

aging (West, Arch Dermatol 130(1):87-95, 1994). As skin ages, it thins, develops wrinkles, discolors, and heals poorly. Skin cells divide quickly in response to stress and trauma; but, over time, there are fewer and fewer actively dividing skin cells. Compounding the loss of replicative capacity in aging skin is a corresponding loss of support tissues. The number of blood vessels in the skin decreases with age, reducing the nutrients that reach the skin. Also, aged immune cells less effectively fight infection. Nerve cells have fewer branches, slowing the response to pain and increasing the chance of trauma. In aged skin, there are also fewer fat cells, increasing susceptibility to cold and temperature changes. Old skin cells respond more slowly and less accurately to external signals. They produce less vitamin D, collagen, and elastin, allowing the extracellular matrix to deteriorate. As skin thins and loses pigment with age, more ultraviolet light penetrates and damages skin. To repair the increasing ultraviolet damage, skin cells need to divide to replace damaged cells, but aged skin cells have shorter telomeres and are less capable of dividing (Fossel, REVERSING HUMAN AGING. William Morrow & Company, New York City, 1996).

By practicing the subject methods, e.g., via administration of an active agent topically, one can extend telomere length, and slow the downward spiral that skin experiences with age. Such a product not only helps protect a person against the impairments of aging skin; it also permits rejuvenated skin cells to restore youthful immune resistance and appearance. The subject methods can be used for both medical and cosmetic skin rejuvenation applications.

Yet another disease condition in which the subject methods find use in the treatment of osteoporosis. Two types of cells interplay in osteoporosis: osteoblasts make bone and osteoclasts destroy it. Normally, the two are in balance and maintain a constant turnover of highly structured bone. In youth, bones are resilient, harder to break, and heal quickly. In old age, bones are brittle, break easily, and heal slowly and often improperly. Bone loss has been postulated to occur because aged osteoblasts, having lost much of their replicative capacity, cannot continue to divide at the rate necessary to maintain balance (Hazzard et al. PRINCIPLES OF GERIATRIC MEDICINE AND GERONTOLOGY, 2d ed. McGraw-Hill, New York City, 1994). The subject methods can be

employed to lengthen telomeres of osteoblast and osteoclast stem cells, thereby encouraging bone replacement and proper remodeling and reinforcement. The resultant stronger bone improves the quality of life for the many sufferers of osteoporosis and provides savings from fewer fracture treatments. The subject methods are generally part of a comprehensive treatment regime that also includes calcium, estrogen, and exercise.

Additional disease conditions in which the subject methods find use are described in WO 99/35243, the disclosures of which are herein incorporated by reference.

In addition to the above described methods, the subject methods can also be used to extend the lifetime of a mammal. By extend the lifetime is meant to increase the time during which the animal is alive, where the increase is generally at least 1 %, usually at least 5% and more usually at least about 10 %, as compared to a control.

As indicated above, instead of a multicellular animal, the target may be a cell or population of cells which are treated according to the subject methods and then introduced into a multicellular organism for therapeutic effect. For example, the subject methods may be employed in bone marrow transplants for the treatment of cancer and skin grafts for burn victims. In these cases, cells are isolated from a human donor and then cultured for transplantation back into human recipients. During the cell culturing, the cells normally age and senesce, decreasing their useful lifespans. Bone marrow cells, for instance, lose approximately 40 % of their replicative capacity during culturing. This problem is aggravated when the cells are first genetically engineered (Decary, Mouly et al. Hum Gene Ther 7(11): 1347-50, 1996). In such cases, the therapeutic cells must be expanded from a single engineered cell. By the time there are sufficient cells for transplantation, the cells have undergone the equivalent of 50 years of aging (Decary, Mouly et al. Hum Gene Ther 8(12): 1429-38, 1997). Use of the subject methods spares the replicative capacity of bone marrow cells and skin cells during culturing and expansion and thus significantly improves the survival and effectiveness of bone marrow and skin cell transplants. Any transplantation technology requiring cell culturing can benefit from the subject methods, including ex vivo gene therapy applications in which cells are cultured outside of the animal and then administered to the

animal, as described in U.S. Patent Nos. 6,068,837; 6,027,488; 5,824,655; 5,821,235; 5,770,580; 5,756,283; 5,665,350; the disclosures of which are herein incorporated by reference.

5 Treatment of Disease Conditions by Decreasing TERT Expression

As summarized above, also provided are methods for enhancing repression of TERT expression, where by enhancement of TERT expression repression is meant a decrease in TERT expression by a factor of at least
10 about 2 fold, usually at least about 5 fold and more usually at least about 10 fold, as compared to a control. Methods for enhancing Site C mediated repression of TERT expression find use in, among other applications, the treatment of cellular proliferative disease conditions, particularly abnormal cellular proliferative disease conditions, including, but not limited to, neoplastic
15 disease conditions, e.g., cancer. In such applications, an effective amount of an active agent, e.g., a Site C repressor protein, analog or mimetic thereof, a vector encoding a Site C repressor protein or active fragment thereof, an agent that enhances endogenous Site C repressor activity, an agent that enhances expression of Site C repressor protein, etc., is administered to the subject in
20 need thereof. Treatment is used broadly as defined above, e.g., to include at least an amelioration in one or more of the symptoms of the disease, as well as a complete cessation thereof, as well as a reversal and/or complete removal of the disease condition, e.g., cure. Methods of treating disease conditions resulting from unwanted TERT expression, such as cancer and
25 other diseases characterized by the presence of unwanted cellular proliferation, are described in, for example, U.S. Patent Nos. 5,645,986; 5,656,638; 5,703,116; 5,760,062; 5,767,278; 5,770,613; and 5,863,936; the disclosures of which are herein incorporated by reference.

30 NUCLEIC ACID COMPOSITIONS

Also provided by the subject invention are nucleic acid compositions, where the compositions are present in other than their natural environment, e.g., are isolated, recombinant, etc., that include a Site C repressor binding

site/domain/region, as described above. In other embodiments, the subject nucleic acids have a sequence that is substantially the same as, or identical to, the Site C repressor binding site sequences as described above, e.g., SEQ ID NOs: 01 to 04. A given sequence is considered to be substantially similar to
5 this particular sequence if it shares high sequence similarity with the above described specific sequences, e.g. at least 75% sequence identity, usually at least 90%, more usually at least 95% sequence identity with the above specific sequences. Sequence similarity is calculated based on a reference sequence, which may be a subset of a larger sequence. A reference sequence will
10 usually be at least about 18 nt long, more usually at least about 30 nt long, and may extend to the complete sequence that is being compared. Algorithms for sequence analysis are known in the art, such as BLAST, described in Altschul *et al.* (1990), *J. Mol. Biol.* 215:403-10 (using default settings, i.e. parameters $w=4$ and $T=17$). Of particular interest in certain embodiments are nucleic
15 acids of substantially the same length as the specific nucleic acid identified above, where by substantially the same length is meant that any difference in length does not exceed about 20 number %, usually does not exceed about 10 number % and more usually does not exceed about 5 number %; and have sequence identity to this sequence of at least about 90%, usually at least
20 about 95% and more usually at least about 99% over the entire length of the nucleic acid.

Also provided are nucleic acids that hybridize to the above described nucleic acid under stringent conditions. An example of stringent hybridization conditions is hybridization at 50°C or higher and 0.1×SSC (15 mM sodium
25 chloride/1.5 mM sodium citrate). Another example of stringent hybridization conditions is overnight incubation at 42°C in a solution: 50 % formamide, 5 × SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5 × Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1
30 × SSC at about 65°C. Stringent hybridization conditions are hybridization conditions that are at least as stringent as the above representative conditions, where conditions are considered to be at least as stringent if they are at least about 80% as stringent, typically at least about 90% as stringent as the above specific stringent conditions. Other stringent hybridization conditions are

known in the art and may also be employed to identify nucleic acids of this particular embodiment of the invention.

In many embodiments, the above described nucleic acid compositions include the Site C sequence/domain region but do not include the full
5 sequence of the hTERT minimal promoter. In these embodiments, the subject nucleic acids include no more than about 90 number %, usually no more than about 80 number % and more usually no more than about 75 number %, where in many embodiments the subject nucleic acids include less than about 50 number %, sometimes less than about 40 number % and sometimes less
10 than about 25 number % of the total sequence of the hTERT minimal promoter. In certain embodiments, the length of the subject nucleic acids ranges from about 5 to about 5000 bases, sometimes from about 10 to about 2500 bases and usually from about 10 to about 1000 bases, where in certain embodiments the length ranges from about 10 to about 500 bases, sometimes
15 from about 10 to about 250 bases and sometimes from about 10 to about 100 bases, including from about 10 to about 50 bases.

The above described nucleic acid compositions find use in a variety of different applications, including the preparation of constructs, e.g., vectors, expression systems, etc., as described more fully below, the preparation of
20 probes for the Site C repressor binding site sequence in non-human animals, i.e., non-human Site C repressor binding site homologs, and the like. Where the subject nucleic acids are employed as probes, a fragment of the provided nucleic acid may be used as a hybridization probe against a genomic library from the target organism of interest, where low stringency conditions are used.
25 The probe may be a large or small fragment, generally ranging in length from about 10 to 100 nt, usually from about 15 to 50 nt. Nucleic acids having sequence similarity are detected by hybridization under low stringency conditions, for example, at 50°C and 6×SSC (0.9 M sodium chloride/0.09 M sodium citrate) and remain bound when subjected to washing at 55°C in
30 1×SSC (0.15 M sodium chloride/0.015 M sodium citrate). Sequence identity may be determined by hybridization under stringent conditions, for example, at 50°C or higher and 0.1×SSC (15 mM sodium chloride/0.15 mM sodium citrate). Nucleic acids having a region of substantial identity to the provided nucleic acid sequences bind to the provided sequences under stringent

hybridization conditions. By using probes, particularly labeled probes of DNA sequences, one can isolate homologous or related sequences.

The subject nucleic acids are isolated and obtained in substantial purity, generally as other than an intact chromosome. As such, they are present in
5 other than their naturally occurring environment. Usually, the DNA will be obtained substantially free of other nucleic acid sequences that do not include a Site C repressor binding site sequence or fragment thereof, generally being at least about 50%, usually at least about 90% pure and are typically "recombinant", *i.e.* flanked by one or more nucleotides with which it is not
10 normally associated on a naturally occurring chromosome.

The subject nucleic acids may be produced using any convenient protocol, including synthetic protocols, *e.g.*, those where the nucleic acid is synthesized by a sequential monomeric approach (*e.g.*, via phosphoramidite chemistry); where subparts of the nucleic acid are so synthesized and then
15 assembled or concatamerized into the final nucleic acid, and the like. Where the nucleic acid of interest has a sequence that occurs in nature, the nucleic acid may be retrieved, isolated, amplified *etc.*, from a natural source using conventional molecular biology protocols.

Also provided are nucleic acid compositions that include a modified or
20 altered Site C site, *e.g.*, where the site includes one or more deletions or substitutions as compared to the above specific Site C sequences, including a deletion or substitution of all or portion of the Site C repressor binding site, *e.g.*, preferably a deletion or substitution of at least one nucleotide, in certain embodiments at least four nucleotides within the region of nucleotides from
25 about -40 to about -90, usually from about -45 to about -85 and more usually from about -45 to about -80 relative to the "A" of the telomerase ATG codon, including the specific regions specified above, and usually at least 7 nucleotides from this region, and preferably all nucleotides from this region. Additionally, such a deletion may extend further, for example to include the
30 nucleotides from positions -74 to -58, or subsets thereof, with the exception being deletions that result in the presence of a site which in fact binds to the Site C repressor protein in a manner that enhances TERT expression. The subject nucleic acids of this embodiment that include a deletion (or substitution) in all or a portion of the Site C repressor site of the TERT

promoter may be present in the genome of a cell or animal of interest, e.g., as a "knockout" deletion in a transgenic cell or animal, where the cell or animal initially has this region, or may be present in an isolated form. A "knockout" animal could be produced from an animal that originally has the subject Site C repressor site using the sequences flanking specific Site C regions described here and the basic "knockout" technology known to those skilled in the art e.g. see U.S. Patent 5,464,764 to Capecchi.

Also provided are constructs comprising the subject nucleic acid compositions, e.g., those that include the Site C repressor binding site or those that include a deletion in the Site C repressor binding site, inserted into a vector, where such constructs may be used for a number of different applications, including propagation, screening, genome alteration, and the like, as described in greater detail below. Constructs made up of viral and non-viral vector sequences may be prepared and used, including plasmids, as desired.

The choice of vector will depend on the particular application in which the nucleic acid is to be employed. Certain vectors are useful for amplifying and making large amounts of the desired DNA sequence. Other vectors are suitable for expression in cells in culture, e.g., for use in screening assays. Still other vectors are suitable for transfer and expression in cells in a whole animal or person. The choice of appropriate vector is well within the skill of the art. Many such vectors are available commercially. To prepare the constructs, the partial or full-length nucleic acid is inserted into a vector typically by means of DNA ligase attachment to a cleaved restriction enzyme site in the vector. Alternatively, the desired nucleotide sequence can be inserted by homologous recombination in vivo. Typically this is accomplished by attaching regions of homology to the vector on the flanks of the desired nucleotide sequence. Regions of homology are added by ligation of oligonucleotides, or by polymerase chain reaction using primers comprising both the region of homology and a portion of the desired nucleotide sequence, for example.

Additional examples of nucleic acid compositions that include the Site C repressor binding site are polymers, e.g. a double stranded DNA molecules, that mimic the Site C repressor site as described above. Also of interest are anti-sense sequences which are sufficiently homologous to the Site C binding

site, such that they are useful to block attachment of the repressor protein to the Site C repressor binding site.

Also provided are expression cassettes, vectors or systems that find use in, among other applications, screening for agents that modulate, e.g.,
5 inhibit or enhance the repressive activity of the region, as described in greater detail below; and/or to provide for expression of proteins under the control of the expression regulation mechanism of the TERT gene. By expression cassette or system is meant a nucleic acid that includes a sequence encoding a peptide or protein of interest, i.e., a coding sequence, operably linked to a
10 promoter sequence, where by operably linked is meant that expression of the coding sequence is under the control of the promoter sequence. The expression systems and cassettes of the subject invention comprise a Site C repressor binding site/region operably linked to the promoter, where the promoter is, in many embodiments, a TERT promoter, such as the hTERT
15 promoter. See e.g., the hTERT promoter sequence described in Cong et al., Hum. Mol. Genet. (1999) 8:137-142.

As indicated above, expression systems comprising the subject regions find use in applications where it is desired to control expression of a particular coding sequence using the TERT transcriptional mechanism. In such
20 applications, the expression system further includes the coding sequence of interest operably linked to the TERT promoter/Site C repressor binding site elements. The expression system is then employed in an appropriate environment to provide expression or non-expression of the protein, as desired, e.g., in an environment in which telomerase is expressed, e.g., a HeLa
25 cell, or in an environment in which telomerase is not expressed, e.g., an MRC5 cell. Alternatively, the expression system may be used in an environment in which telomerase expression is inducible, e.g., by adding to the system an additional agent that turns on telomerase expression.

The above applications of the subject nucleic acid compositions are
30 merely representative of the diverse applications in which the subject nucleic acid compositions find use.

GENERATION OF ANTIBODIES

Also provided are methods of generating antibodies, e.g., monoclonal antibodies. In one embodiment, the blocking or inhibition, either directly or indirectly as described above, of the Site C repressor site/Site C repressor interaction is used to immortalize cells in culture, e.g., by enhancing telomerase expression. Exemplary of cells that may be used for this purpose are non-transformed antibody producing cells, e.g. B cells and plasma cells which may be isolated and identified for their ability to produce a desired antibody using known technology as, for example, taught in U.S. patent 5,627,052. These cells may either secrete antibodies (antibody-secreting cells) or maintain antibodies on the surface of the cell without secretion into the cellular environment. Such cells have a limited lifespan in culture, and are usefully immortalized by upregulating expression of telomerase using the methods of the present invention.

Because the above described methods are methods of increasing expression of TERT and therefore increasing the proliferative capacity and/or delaying the onset of senescence in a cell, they find applications in the production of a range of reagents, typically cellular or animal reagents. For example, the subject methods may be employed to increase proliferation capacity, delay senescence and/or extend the lifetimes of cultured cells. Cultured cell populations having enhanced TERT expression are produced using any of the protocols as described above, including by contact with an agent that inhibits repressor region transcription repression and/or modification of the repressor region in a manner such that it no longer represses TERT coding sequence transcription, etc.

The subject methods find use in the generation of monoclonal antibodies. An antibody-forming cell may be identified among antibody-forming cells obtained from an animal which has either been immunized with a selected substance, or which has developed an immune response to an antigen as a result of disease. Animals may be immunized with a selected antigen using any of the techniques well known in the art suitable for generating an immune response. Antigens may include any substance to which an antibody may be made, including, among others, proteins,

carbohydrates, inorganic or organic molecules, and transition state analogs that resemble intermediates in an enzymatic process. Suitable antigens include, among others, biologically active proteins, hormones, cytokines, and their cell surface receptors, bacterial or parasitic cell membrane or purified
5 components thereof, and viral antigens.

As will be appreciated by one of ordinary skill in the art, antigens which are of low immunogenicity may be accompanied with an adjuvant or hapten in order to increase the immune response (for example, complete or incomplete Freund's adjuvant) or with a carrier such as keyhole limpet hemocyanin (KLH).

10 Procedures for immunizing animals are well known in the art. Briefly, animals are injected with the selected antigen against which it is desired to raise antibodies. The selected antigen may be accompanied by an adjuvant or hapten, as discussed above, in order to further increase the immune response. Usually the substance is injected into the peritoneal cavity, beneath the skin,
15 or into the muscles or bloodstream. The injection is repeated at varying intervals and the immune response is usually monitored by detecting antibodies in the serum using an appropriate assay that detects the properties of the desired antibody. Large numbers of antibody-forming cells can be found in the spleen and lymph node of the immunized animal. Thus, once an
20 immune response has been generated, the animal is sacrificed, the spleen and lymph nodes are removed, and a single cell suspension is prepared using techniques well known in the art.

Antibody-forming cells may also be obtained from a subject which has generated the cells during the course of a selected disease. For instance,
25 antibody-forming cells from a human with a disease of unknown cause, such as rheumatoid arthritis, may be obtained and used in an effort to identify antibodies which have an effect on the disease process or which may lead to identification of an etiological agent or body component that is involved in the cause of the disease. Similarly, antibody-forming cells may be obtained from
30 subjects with disease due to known etiological agents such as malaria or AIDS. These antibody forming cells may be derived from the blood or lymph nodes, as well as from other diseased or normal tissues. Antibody-forming cells may be prepared from blood collected with an anticoagulant such as heparin or EDTA. The antibody-forming cells may be further separated from

erythrocytes and polymorphs using standard procedures such as centrifugation with Ficoll-Hypaque (Pharmacia, Uppsala, Sweden). Antibody-forming cells may also be prepared from solid tissues such as lymph nodes or tumors by dissociation with enzymes such as collagenase and trypsin in the presence of EDTA.

Antibody-forming cells may also be obtained by culture techniques such as in vitro immunization. Briefly, a source of antibody-forming cells, such as a suspension of spleen or lymph node cells, or peripheral blood mononuclear cells are cultured in medium such as RPMI 1640 with 10% fetal bovine serum and a source of the substance against which it is desired to develop antibodies. This medium may be additionally supplemented with amounts of substances known to enhance antibody-forming cell activation and proliferation such as lipopolysaccharide or its derivatives or other bacterial adjuvants or cytokines such as IL-1, IL-2, IL-4, IL-5, IL-6, GM-CSF, and IFN- γ . To enhance immunogenicity, the selected antigen may be coupled to the surface of cells, for example, spleen cells, by conventional techniques such as the use of biotin/avidin as described below.

Antibody-forming cells may be enriched by methods based upon the size or density of the antibody-forming cells relative to other cells. Gradients of varying density of solutions of bovine serum albumin can also be used to separate cells according to density. The fraction that is most enriched for desired antibody-forming cells can be determined in a preliminary procedure using the appropriate indicator system in order to establish the antibody-forming cells.

The identification and culture of antibody producing cells of interest is followed by enhancement of TERT expression in these cells by the subject methods, thereby avoiding the need for the immortalization/fusing step employed in traditional hybridoma manufacture protocols. In such methods, the first step is immunization of the host animal with an immunogen, typically a polypeptide, where the polypeptide will preferably be in substantially pure form, comprising less than about 1% contaminant. The immunogen may comprise the complete protein, fragments or derivatives thereof. To increase the immune response of the host animal, the protein may be combined with an adjuvant, where suitable adjuvants include alum, dextran sulfate, large

polymeric anions, oil & water emulsions, e.g. Freund's adjuvant, Freund's complete adjuvant, and the like. The protein may also be conjugated to synthetic carrier proteins or synthetic antigens. A variety of hosts may be immunized to produce the subject antibodies. Such hosts include rabbits, guinea pigs, rodents (e.g. mice, rats), sheep, goats, and the like. The protein is administered to the host, usually intradermally, with an initial dosage followed by one or more, usually at least two, additional booster dosages. Following immunization, generally, the spleen and/or lymph nodes of an immunized host animal provide a source of plasma cells. The plasma cells are treated according to the subject invention to enhance TERT expression and thereby, increase the proliferative capacity and/or delay senescence to produce "pseudo" immortalized cells. Culture supernatant from individual cells is then screened using standard techniques to identify those producing antibodies with the desired specificity. Suitable animals for production of monoclonal antibodies to a human protein include mouse, rat, hamster, etc. To raise antibodies against the mouse protein, the animal will generally be a hamster, guinea pig, rabbit, etc. The antibody may be purified from the cell supernatants or ascites fluid by conventional techniques, e.g. affinity chromatography using RFLAT-1 protein bound to an insoluble support, protein A sepharose, etc.

In an analogous fashion, the subject methods are employed to enhance TERT expression in non-human animals, e.g., non-human animals employed in laboratory research. Using the subject methods with such animals can provide a number of advantages, including extending the lifetime of difficult and/or expensive to produce transgenic animals. As with the above described cells and cultures thereof, the expression of TERT in the target animals may be enhanced using a number of different protocols, including the administration of an agent that inhibits Site C repressor protein repression and/or targeted disruption of the Site C repressor binding site. The subject methods may be used with a number of different types of animals, where animals of particular interest include mammals, e.g., rodents such as mice and rats, cats, dogs, sheep, rabbits, pigs, cows, horses, and non-human primates, e.g. monkeys, baboons, etc.

SCREENING ASSAYS

Also provided by the subject invention are screening protocols and assays for identifying agents that modulate, e.g., inhibit or enhance, Site C repression of TERT transcription. The screening methods include assays that provide for qualitative/quantitative measurements of TERT promoter controlled expression, e.g., of a coding sequence for a marker or reporter gene, in the presence of a particular candidate therapeutic agent. Assays of interest include assays that measures the TERT promoter controlled expression of a reporter gene (i.e. coding sequence, e.g., luciferase, SEAP, etc.) in the presence and absence of a candidate inhibitor agent, e.g., the expression of the reporter gene in the presence or absence of a candidate agent. The screening method may be an *in vitro* or *in vivo* format, where both formats are readily developed by those of skill in the art. Whether the format is *in vivo* or *in vitro*, an expression system, e.g., a plasmid, that includes a Site C repressor binding site, a TERT promoter and a reporter coding sequence all operably linked is combined with the candidate agent in an environment in which, in the absence of the candidate agent, the TERT promoter is repressed, e.g., in the presence of the Site C repressor protein that interacts with the Site C repressor binding site and causes TERT promoter repression. The conditions may be set up *in vitro* by combining the various required components in an aqueous medium, or the assay may be carried out *in vivo*, e.g., in a cell that normally lacks telomerase activity, e.g., an MRC5 cell, etc.

A variety of different candidate agents may be screened by the above methods. Candidate agents encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 50 and less than about 2,500 daltons. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides,

fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof.

Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means
5 are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced
10 libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, *etc.* to produce structural analogs.

15 Agents identified in the above screening assays that inhibit Site C repression of TERT transcription find use in the methods described above, e.g., in the enhancement of TERT expression. Alternatively, agents identified in the above screening assays that enhance Site C repression find use in applications where inhibition of TERT expression is desired, e.g., in the
20 treatment of disease conditions characterized by the presence of unwanted TERT expression, such as cancer and other diseases characterized by the presence of unwanted cellular proliferation, where such methods are described in, for example, U.S. Patent Nos. 5,645,986; 5,656,638; 5,703,116; 5,760,062; 5,767,278; 5,770,613; and 5,863,936; the disclosures of which are
25 herein incorporated by reference.

30

The following examples are offered by way of illustration and not by way of limitation.

EXPERIMENTAL

I. Deletion Experiments

118 deletions of the minimal telomerase promoter as shown in Figure 1
 5 were constructed (using site specific in vitro mutagenesis as described in U.S.
 Patent No. 5,702,931, the disclosure of which is herein incorporated by
 reference) to find regions within the telomerase promoter that contain potential
 repressor sites. These deletions ranged in size from 10 to 300 bases. Each
 deletion version of the minimal promoter was tested for its ability to express
 10 SEAP in MRC5 and HELA. Several of the deletions, all mapping about 50-100
 bases upstream of the telomerase translation initiation codon (ATG), showed
 ~10 fold increased expression. The region was called the Site C region. The
 highest expression in MRC5 was obtained with the deletion called 11K. This
 30 base deletion includes bases -48 to -77 relative to the translation initiation
 15 codon ATG. However, a similar deletion, called 12K, that includes bases -48
 to -57 results in 500 fold less expression. On the other hand, when 11K and
 12K were compared in HELA, they both gave equivalent amounts of
 expression. The repressor site in the Site C region therefore is contained, or
 overlaps with, the 20 bases present in 12K and absent in 11K (i.e. -58 to -77).

20 To identify more specifically the bases that make up this repressor site,
 additional deletions were made. Each deletion is 10 bases long with 7 to 8
 base overlaps between consecutive deletions. The deletions were made in
 the minimal telomerase promoter in the plasmid designated pSSI20 (the full
 annotated sequence of pSSI20 is provided in Figure 2). Each deletion mutant
 25 was independently made three times and all deletions were transiently
 transfected into MRC5 (telomerase negative normal cells) and HELA
 (telomerase positive immortal cells).

A portion of the 5' untranslated region is shown below, from -77 to 1,
 the start of translation. The repressor site extends from -77 to -48, as shown.

30 (SEQ ID NO.: 7)
 CTCCTCGC GCGCGAGTT TCAGGCAGCG CTGCGTCCTG CTGCGCACGT GGGAAGCCCT

 repressor site (-77 to -48)
 35 GGCCCCGGCC ACCCCCGCGA
 □
 start codon (1)

Of particular interest are sequences with a deletion extending from -67 to -58, comprising the nucleotides CGCGAGTTTC (SEQ ID NO:03).

The expression levels were measured using the Secreted Alkaline Phosphatase Assay (SEAP Assay) commercially available from Clontech
5 (Palo Alto, CA). The results are shown below.

Deletion	MRC5	HELA
NONE (control)	0.1931	78.3076
-104 to -95	0.19	78.30
-102 to -93	4.92	73.97
-99 to -90	1.19	86.95
-97 to -88	1.69	97.94
-94 to -85	8.06	89.6
-92 to -83	7.89	89.86
-89 to -80	12.00	93.91
-87 to -78	7.26	59.74
-84 to -75	7.77	85.48
-82 to -73	4.83	99.4
-79 to -70	3.79	73.34
-77 to -68	17.15	82.26
-74 to -65	34.44	78.99
-72 to -63	33.22	123.8
-69 to -60	33.15	133.56
-67 to -58	56.98	97.74
-64 to -55	21.82	127.32
-62 to -53	4.60	108
-59 to -50	19.58	103.1

The column of deletions indicates the bases that were deleted in the repressor site, which is indicated relative to the AUG start codon. The columns for
10 MRC5 and HELA show the level of expression observed for each deletion, reported as a percentage of the SV40 early promoter, which was used to normalize the two cell lines.

The data demonstrate that the deletion from "-67 to -58" gave a reading of 56.9852, as compared to a reading of 0.193109 in the control cells with no deletion in the promoter, giving an increase of 295 fold higher expression. This same deletion gave only 97.746 in HELA cells, compared to the undeleted control value of 78.3076, resulting in a 1.25 fold higher expression. This indicates that a repressor function operates in MRC5 cells to repress expression of the wild type telomerase promoter. When the expression level of deletion "-67 to -58" in MRC5 is compared to the wild type promoter in HELA it is observed that the deletion resulted in almost as much expression as the levels observed in HELA that are sufficient to maintain telomere length. That is, the expression of the deletion in MRC5 was $59.9852/78.3076 = 77\%$ of the wild type in HELA. This indicates that depressing the repressor in MRC5 allows for sufficient amounts of telomerase expression to maintain the length of the telomeres in the cells during cell division, and to stop cellular aging in these cells.

II. Identification of E2F consensus sequence

The Site C region described above was analyzed for the presence of consensus sequences and an E2F transcription factor binding site consensus sequence (E2F-Q6) was identified (see below) utilizing software and databases provided by Genomatix (<http://genomatix.gsf.de>). This identified consensus sequence is located at -68 to -58 of the TERT promoter, or:

(SEQ ID NO.: 7)
 CTCCTCGC GCGCGAGTT TCAGGCAGCG CTGCGTCCTG CTGCGCACGT GGGGAAGCCCT

 repressor site (-68 to -58)

GGCCCCGGCC ACCCCGCGA
 □
 start codon (1)

The identified consensus sequence, E2F-Q6, includes all of above described -67 to -58 deletion plus one base upstream. As can be seen from the above results, every deletion that overlaps this -67 to -58 site causes an elevation in expression with maximum expression occurring from the deletion of bases -67 to -58. The only exception to this general rule is the deletion from

-62 to -53. This deletion actually, accidentally, creates a new sequence that matches the consensus E2F-Q6 sequence better than the original -67 to -58 site does.

5 III. Fine Mapping of the Site C Site

A "fine mapping" analysis of the Site C binding site was completed to determine the effect of each base within site C on telomerase repression and the results are tabulated below and shown graphically in Figure 3. The "fine
10 mapping" analysis involved single base mutations or deletions within Site C and assayed for their affects on the TERT promoter's ability to drive the expression of the SEAP reporter gene in transient transfection assays. In the graph of Figure 3 the letters on the X-axis labeled "before" are the bases of Site C before mutagenesis. The letters labeled "after" are what the bases
15 were changed to by in vitro mutagenesis. In this experiment only one base was changed at a time. That is, in one plasmid the C at -70 was changed to an A. That was the only change that took place in the plasmid. In another plasmid A at -63 was changed to a T. Again, that was the only change that took place in the plasmid. Each plasmid was then transiently transfected into
20 MRC5 cells and expression of SEAP was assayed. The first data point shows the expression of SEAP under control of the wild type telomerase minimal promoter. This shows almost zero (83.10 SEAP units) expression. The next data point shows SEAP expression when the entire 10 base Site C sequence (SEQ ID NO. 03) is deleted. All the subsequent data points show the
25 expression resulting from each of the single base changes shown in the X-axis.

This analysis resulted in the identification of the specific bases within site C that control the regulation of the telomerase promoter. Bases within the site C repressor binding site which were found to be influential in telomerase
30 repression are shown in the site C sequence below as capital letters while those bases when mutated or deleted had little or no effect on telomerase repression are shown in small case.

Site C "fine mapping" results- CGCGagtTTc SEQ ID NO. 08

These results also show that the sequence that the Site C binding protein binds to is GGCGCGAGTTTCA (SEQ ID NO:02).

<u>Plasmid</u>	<u>Base #</u>	<u>Mutation</u>	<u>SEAP</u>
pSSI20		Wild Type	83.10
pSSI304		-67 to -58 deleted	3093.70
pSSI658	-72	G->C	268.37
pSSI663	-71	A->G	208.63
pSSI664	-70	A->C	256.93
pSSI667	-69	C->G	596.70
pSSI552	-68	C->G	879.20
pSSI645	-67	G->C	1841.70
pSSI670	-66	C->G	3021.37
pSSI673	-65	A->C	3274.37
pSSI677	-64	A->G	2115.03
pSSI679	-63	T->A	968.70
pSSI682	-62	C->G	542.80
pSSI686	-61	C->T	1286.37
pSSI688	-60	C->T	2032.37
pSSI691	-59	A->T	2005.03
pSSI694	-58	A->C	1328.70
pSSI697	-57	T->A	1047.03
pSSI700	-56	A->G	66.27
pSSI703	-55	A->G	185.03
pSSI706	-54	G->C	369.03
pSSI710	-53	G->A	237.70

5 IV. Gel Shift Characterization of the Site C Site

The following oligos (each one was made double stranded) were employed in gel shift experiments using nuclear extracts from the normal cell line

IMR90 and the immortal cell line Raji (Nuclear extracts of IMR90, Catalog

- 10 #1012217, and Raji, Catalog #100156 were purchased from Geneka Biotechnology Inc.). IMR90 cells can be obtained from ATCC Catalog #CCL-186. Raji cells can be obtained from ATCC Catalog #CCL-86.). The gel shift protocol that was followed is from the BandShift Kit, Amersham Pharmacia Biotech, XY-026-00-06. The following changes to their protocol were made:
- 15 the binding reaction is at 4C for 1 hour and no loading dye is added prior to electrophoresis. The results were identical for IMR90 and Raji. The ability of each oligo to shift in a gel shift assay, using either nuclear extract, when radioactively labeled are shown below.

<u>Oligo</u>		
<u>Name</u>	<u>Result</u>	<u>Sequence</u>
SSI586	No Shift	TCTCCTCGCGGCGAGTTTCAGG (SEQ ID NO:09)
SSI584	No Shift	TCTCCTCGCGGCGAGTTTCAGGCA (SEQ ID NO:10)
5 SSI582	No Shift	TCTCCTCGCGGCGAGTTTCAGGCAGC (SEQ ID NO:11)
SSI614	Weak Shift	TCTCCTCGCGGCGAGTTTCAGGCAGCG (SEQ ID NO:12)
SSI570	Strong Shift	TCTCCTCGCGGCGAGTTTCAGGCAGCGC (SEQ ID NO:13)
SSI630	Strong Shift	CTCGCGGCGAGTTTCAGGCAGCGCTG (SEQ ID NO:14)
SSI570	Strong Shift	TCTCCTCGCGGCGAGTTTCAGGCAGCGC (SEQ ID NO:15)
10 SSI572	Strong Shift	TCCTCGCGGCGAGTTTCAGGCAGCGC (SEQ ID NO:16)
SSI574	Strong Shift	CTCGCGGCGAGTTTCAGGCAGCGC (SEQ ID NO:17)
SSI634	Strong Shift	CGCGGCGAGTTTCAGGCAGCGCTGCGTC (SEQ ID NO:18)
SSI636	Strong Shift	CGCGCGAGTTTCAGGCAGCGCTGCGTC (SEQ ID NO:19)
SSI638	Weak Shift	GCGCGAGTTTCAGGCAGCGCTGCGTC (SEQ ID NO:20)
15 SSI640	Weak Shift	CGCGAGTTTCAGGCAGCGCTGCGTC (SEQ ID NO:21)
SSI642	Weak Shift	GCGAGTTTCAGGCAGCGCTGCGTC (SEQ ID NO:22)

The following mutant gel shift oligo (double stranded) in

which base -65 (relative to the ATG of telomerase) was converted from a

20 C to an A (shown in green) was also assayed.

TCTCCTCGCGGCGAGAGTTTCAGGCAGCGC (SEQ ID NO:23)

Previous SEAP assays (See Experiment "III. Fine Mapping of the Site C Site"

25 above) had shown that this mutation abolished repressor binding as much as the complete deletion of the original 10 base site C sequence (SEQ ID NO:03). This mutant oligo did not cause a shift, indicating that the gel shift data agrees with the expression data.

30 As such, the following sequence is another Site C sequence:

GGCGCGAGTTTCAGGCAGCGC (SEQ ID NO:04)

It is evident from the above results and discussion that the subject
 35 invention provides important new nucleic acid compositions that find use in a variety of applications, including the establishment of expression systems that exploit the regulatory mechanism of the TERT gene and the establishment of screening assays for agents that enhance TERT expression. In addition, the subject invention provides methods of enhancing TERT expression in a
 40 cellular or animal host, which methods find use in a variety of applications, including the production of scientific research reagents and therapeutic treatment applications. Accordingly, the subject invention represents significant contribution to the art.

All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference. The
5 citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

Although the foregoing invention has been described in some detail by
10 way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

WHAT IS CLAIMED IS:

1. A method of modulating expression of TERT from a TERT expression system that includes a TERT promoter and a Site C repressor binding site,
5 said method comprising:
modulating TERT transcription repression by said Site C repressor binding site.
2. The method according to Claim 1, wherein said expression system is
10 present in a cell-free environment.
3. The method according to Claim 1, wherein said expression system is present inside of a cell.
- 15 4. The method according to Claim 1, wherein said expression system comprises a TERT genomic sequence.
5. The method according to Claim 1, wherein said method is a method of enhancing TERT expression.
20
6. The method according to Claim 5, wherein TERT expression is enhanced by inhibiting Site C repression of TERT expression.
7. The method according to Claim 6, wherein said inhibiting is by
25 contacting said expression system with an agent that at least decreases the transcription repression activity of said Site C repressor binding site.
8. The method according to Claim 7, wherein said agent comprises a nucleic acid.
30
9. The method according to Claim 7, wherein said agent comprises a peptide or a protein.

10. The method according to Claim 7, wherein said agent is a small molecule.
11. A method for enhancing telomerase expression in a cell comprising a telomerase gene, said method comprising:
administering to said cell an effective amount of an agent that inhibits Site C TERT transcription repression.
12. The method according to Claim 11, wherein said administering is *ex vivo*.
13. The method according to Claim 11, wherein said administering is *in vivo*.
14. The method according to Claim 11, wherein said method is a method for increasing the proliferative capacity of said cell.
15. The method according to Claim 11, wherein said method is a method for delaying senescence of said cell.
16. A method for enhancing telomerase expression in a mammal, said method comprising:
administering to said mammal an effective amount of an agent that inhibits Site C repression of TERT transcription.
17. The method according to Claim 16, wherein said agent is an agent that at least decreases the transcription repression activity of said Site C repressor binding site.
18. The method according to Claim 17, wherein said agent comprises a nucleic acid.

19. The method according to Claim 17, wherein said agent comprises a peptide or a protein.
20. The method according to Claim 17, wherein said agent is a small molecule.
21. The method according to Claim 16, wherein said method extends the lifespan of said mammal.
22. The method according to Claim 16, wherein said mammal is a human.
23. A method for decreasing telomerase expression in a cell comprising a telomerase gene, said method comprising:
administering to said cell an effective amount of an agent that enhances Site C TERT transcription repression.
24. The method according to Claim 23, wherein said administering is *ex vivo*.
25. The method according to Claim 23, wherein said administering is *in vivo*.
26. The method according to Claim 23, wherein said method is a method for decreasing the proliferative capacity of said cell.
27. A method for decreasing telomerase expression in a mammal, said method comprising:
administering to said mammal an effective amount of an agent that enhances Site C repression of TERT transcription.
28. The method according to Claim 27, wherein said agent is an agent that at least enhances the transcription repression activity of said Site C repressor binding site.

29. The method according to Claim 28, wherein said agent comprises a nucleic acid.
30. The method according to Claim 28, wherein said agent comprises a peptide or a protein.
31. The method according to Claim 27, wherein said method is a method of treating a disease condition resulting from telomerase activity.
32. The method according to Claim 31, wherein said disease condition is characterized by abnormal cellular proliferation.
33. The method according to Claim 32, wherein said disease condition is cancer.
34. A nucleic acid present in other than its natural environment, wherein said nucleic acid has a nucleotide sequence that is the same as or substantially identical to the Site C repressor binding site and said nucleic acid does not include the full minimal Tert promoter sequence.
35. The nucleic acid according to Claim 34, wherein said nucleic acid has a length ranging from about 1 to about 50 bases.
36. The nucleic acid according to Claim 34, wherein said nucleic acid is isolated
37. The nucleic acid according to Claim 34, wherein said nucleic acid has a sequence that is substantially the same as or identical to a sequence found in a sequence selected from the group consisting of SEQ ID NOs:01 to 04.
38. An isolated nucleic acid or mimetic thereof that hybridizes under stringent conditions to the nucleic acid according to Claims 34 to 37 or its complementary sequence, wherein said isolated nucleic acid does not include the full TERT minimal promoter sequence.

39. A construct comprising a nucleic acid according to Claims 34 to 38.
40. The construct according to Claim 39, wherein said construct comprises a TERT promoter.
41. The construct according to Claim 39, wherein said construct is an expression cassette.
42. A double stranded DNA decoy sequence comprising a Site C repressor binding site.
43. The decoy according to Claim 42, wherein said decoy comprises a sequence selected from the group consisting of SEQ ID NOs: 01 to 04.
44. The decoy according to Claim 42, wherein said decoy ranges in length from about 10 to about 50 bases.
45. A method of treatment comprising administering to cells a decoy according to Claim 42.
46. A method of determining whether an agent that inhibits Site C repression of TERT transcription, said method comprising:
- (a) contacting said agent with an expression system comprising a Site C repressor binding site and a coding sequence operably linked to a TERT promoter under conditions such that in the absence of said agent transcription of said coding sequence is repressed;
 - (b) determining whether transcription of said coding sequence is repressed in the presence of said agent; and
 - (c) identifying said agent as an agent inhibits Site C repression of TERT transcription if transcription of said coding sequence is not repressed in the presence of said agent.

47. The method according to Claim 46, wherein said contacting step occurs in a cell-free environment.
48. The method according to Claim 46, wherein said contacting step occurs in a cell.
49. The method according to Claim 46, wherein said agent is a small molecule.
50. A mammalian cell comprising a telomerase gene modified by deletion of any of the nucleotides found in a Site C repressor.
51. The cell according to Claim 50, wherein said deletion is any of nucleotides found in a sequence selected from the group consisting of SEQ ID NOs: 01 to 04.
52. A method of producing a mammalian antibody, comprising the steps of:
isolating a B cell from a mammal, which B cell or its progeny cell is characterized by producing an antibody of interest;
enhancing telomerase expression in said B cell by the method of Claim 11; and
growing the immortalized B cell and its progeny under conditions which allow the cells to produce the antibody of interest.

Figure 1

```

-258      -250      -240      -230      -220      -210
  |         |         |         |         |         |
CCAGGACC GCGCTCCCA CGTGGCGGAG GGACTGGGGA CCCGGGCACC CGTCCTGCCC

-200      -190      -180      -170      -160      -150
  |         |         |         |         |         |
CTTCACCTTC CAGCTCCGCC TCCTCCGCGC GGACCCCGCC CCGTCCCGAC CCCTCCCGGG

-140      -130      -120      -110      -100      -90
  |         |         |         |         |         |
TCCCCGGGCC AGCCCCCTCC GGGCCCTCCC AGCCCCCTCCC CTTCTTTTCC GCGGCCCCGC

-80      -70      -60      -50      -40      -30
  |         |         |         |         |         |
CCTCTCCTCG CGGCGCGAGT TTCAGGCAGC GCTGCGTCCT GCTGCGCACG TGGGAAGCCC

-20      -10      -1
  |         |         |
TGGCCCCGGC CACCCCCGCG ATG

```

(SEQ ID NO:24)

Figure 2

10	20	30	40	50	60
GGTACCGAGC	TCTTACGCGT	GCTAGCCCGG	GCTCGAGCCA	GGACCGCGCT	CCCCACGTGG
70	80	90	100	110	120
CGGAGGGACT	GGGGACCCGG	GCACCCGTCC	TGCCCCCTTCA	CCTTCCAGCT	CCGCCTCCTC
130	140	150	160	170	180
CGCGCGGACC	CCGCCCCGTC	CCGACCCCTC	CCGGGTCCCC	GGCCAGCCCC	CCTCCGGGGC
190	200	210	220	230	240
CTCCCAGCCC	CTCCCCTTCC	TTTCCGCGGC	CCCGCCCTCT	CCTCGCGGCG	CGAGTTTTCAG
250	260	270	280	290	300
GCAGCGCTGC	GTCCTGCTGC	GCACGTGGGA	AGCCCTGGCC	CCGGCCACCC	CCGCGAATTC
310	320	330	340	350	360
GCCCACCATG	CTGCTGCTGC	TGCTGCTGCT	GGGCCTGAGG	CTACAGCTCT	CCCTGGGCAT
370	380	390	400	410	420
CATCCCAATT	GAGGAGGAGA	ACCCGGACTT	CTGGAACCGC	GAGGCAGCCG	AGGCCCTGGG
430	440	450	460	470	480
TGCCGCCAAG	AAGCTGCAGC	CTGCACAGAC	AGCCGCCAAG	AACCTCATCA	TCTTCCTGGG
490	500	510	520	530	540
CGATGGGATG	GGGGTGTCTA	CGGTGACAGC	TGCCAGGATC	CTAAAAGGGC	AGAAGAAGGA
550	560	570	580	590	600
CAAACCTGGG	CCTGAGATAC	CCCTGGCCAT	GGACCGCTTC	CCATATGTGG	CTCTGTCCAA
610	620	630	640	650	660
GACATACAAT	GTAGACAAAC	ATGTGCCAGA	CAGTGGAGCC	ACAGCCACGG	CCTACCTGTG
670	680	690	700	710	720
CGGGGTCAAG	GGCAACTTCC	AGACCATTGG	CTTGAGTGCA	GCCGCCCGCT	TTAACCAGTG
730	740	750	760	770	780
CAACACGACA	CGCGGCAACG	AGGTCATCTC	CGTGATGAAT	CGGGCCAAGA	AAGCAGGGAA
790	800	810	820	830	840
GTCAGTGGGA	GTGGTAACCA	CCACACGAGT	GCAGCACGCC	TCGCCAGCCG	GCACCTACGC
850	860	870	880	890	900
CCACACGGTG	AACCGCAACT	GGTACTCGGA	CGCCGACGTG	CCTGCCTCGG	CCCGCCAGGA
910	920	930	940	950	960
GGGGTGCCAG	GACATCGCTA	CGCAGCTCAT	CTCCAACATG	GACATTGACG	TGATCCTAGG
970	980	990	1000	1010	1020
TGGAGGCCGA	AAGTACATGT	TTCGCATGGG	AACCCAGAC	CCTGAGTACC	CAGATGACTA
1030	1040	1050	1060	1070	1080
CAGCCAAGGT	GGGACCAGGC	TGGACGGGAA	GAATCTGGTG	CAGGAATGGC	TGGCGAAGCG
1090	1100	1110	1120	1130	1140
CCAGGGTGCC	CGGTATGTGT	GGAACCGCAC	TGAGCTCATG	CAGGCTTCCC	TGGACCCGTC

Figure 2 (cont)

1150	1160	1170	1180	1190	1200
TGTGACCCAT	CTCATGGGTC	TCTTTGAGCC	TGGAGACATG	AAATACGAGA	TCCACCGAGA
1210	1220	1230	1240	1250	1260
CTCCACACTG	GACCCCTCCC	TGATGGAGAT	GACAGAGGCT	GCCCTGCGCC	TGCTGAGCAG
1270	1280	1290	1300	1310	1320
GAACCCCCGC	GGCTTCTTCC	TCTTCGTGGA	GGGTGGTCGC	ATCGACCATG	GTCATCATGA
1330	1340	1350	1360	1370	1380
AAGCAGGGCT	TACCGGGCAC	TGACTGAGAC	GATCATGTTC	GACGACGCCA	TTGAGAGGGC
1390	1400	1410	1420	1430	1440
GGGCCAGCTC	ACCAGCGAGG	AGGACACGCT	GAGCCTCGTC	ACTGCCGACC	ACTCCCACGT
1450	1460	1470	1480	1490	1500
CTTCTCCTTC	GGAGGCTACC	CCCTGCGAGG	GAGCTCCATC	TTCGGGCTGG	CCCCTGGCAA
1510	1520	1530	1540	1550	1560
GGCCCCGGAC	AGGAAGGCCT	ACACGGTCCT	CCTATACGGA	AACGGTCCAG	GCTATGTGCT
1570	1580	1590	1600	1610	1620
CAAGGACGGC	GCCCCGGCCG	ATGTTACCGA	GAGCGAGAGC	GGGAGCCCCG	AGTATCGGCA
1630	1640	1650	1660	1670	1680
GCAGTCAGCA	GTGCCCCCTG	ACGAAGAGAC	CCACGCAGGC	GAGGACGTGG	CGGTGTTTCG
1690	1700	1710	1720	1730	1740
GCGCGGCCCC	CAGGCGCACC	TGGTTCACGG	CGTGCAGGAG	CAGACCTTCA	TAGCGCACGT
1750	1760	1770	1780	1790	1800
CATGGCCTTC	GCCGCCTGCC	TGGAGCCCTA	CACCGCCTGC	GACCTGGCGC	CCCCCGCCGG
1810	1820	1830	1840	1850	1860
CACCACCGAC	GCCGCGCACC	CGGGTTACTC	TAGAGTCGGG	GCGGCCGGCC	GCTTCGAGCA
1870	1880	1890	1900	1910	1920
GACATGATAA	GATACATTGA	TGAGTTTGGG	CAAACCACAA	CTAGAATGCA	GTGAAAAAAA
1930	1940	1950	1960	1970	1980
TGCTTTATTT	GTGAAATTTG	TGATGCTATT	GCTTTATTTG	TAACCATTAT	AAGCTGCAAT
1990	2000	2010	2020	2030	2040
AAACAAGTTA	ACAACAACAA	TTGCATTTCAT	TTTATGTTTC	AGGTTTCAGGG	GGAGGTGTGG
2050	2060	2070	2080	2090	2100
GAGGTTTTTT	AAAGCAAGTA	AAACCTCTAC	AAATGTGGTA	AAATCGATAA	GGATCCGTCG
2110	2120	2130	2140	2150	2160
ACCGATGCCC	TTGAGAGCCT	TCAACCCAGT	CAGCTCCTTC	CGGTGGGCGC	GGGGCATGAC
2170	2180	2190	2200	2210	2220
TATCGTCGCC	GCACCTTATGA	CTGTCTTCTT	TATCATGCAA	CTCGTAGGAC	AGGTGCCGGC
2230	2240	2250	2260	2270	2280
AGCGCTCTTC	CGCTTCCTCG	CTCACTGACT	CGCTGCGCTC	GGTCGTTTCG	CTGCGGCGAG
2290	2300	2310	2320	2330	2340
CGGTATCAGC	TCACTCAAAG	GCGGTAATAC	GGTTATCCAC	AGAATCAGGG	GATAACGCAG

Figure 2 (cont)

2350	2360	2370	2380	2390	2400
GAAAGAACAT	GTGAGCAAAA	GGCCAGCAAA	AGGCCAGGAA	CCGTAAAAAG	GCCGCGTTGC
2410	2420	2430	2440	2450	2460
TGGCGTTTTT	CCATAGGCTC	CGCCCCCCTG	ACGAGCATCA	CAAAAATCGA	CGCTCAAGTC
2470	2480	2490	2500	2510	2520
AGAGGTGGCG	AAACCCGACA	GGACTATAAA	GATACCAGGC	GTTTCCCCCT	GGAAGCTCCC
2530	2540	2550	2560	2570	2580
TCGTGCGCTC	TCCTGTTCCG	ACCCTGCCGC	TTACCGGATA	CCTGTCCGCC	TTTCTCCCTT
2590	2600	2610	2620	2630	2640
CGGGAAGCGT	GGCGCTTTCT	CATAGCTCAC	GCTGTAGGTA	TCTCAGTTTC	GTGTAGGTTC
2650	2660	2670	2680	2690	2700
TTCGCTCCAA	GCTGGGCTGT	GTGCACGAAC	CCCCCGTTCA	GCCCGACCGC	TGCGCCTTAT
2710	2720	2730	2740	2750	2760
CCGGTAACTA	TCGTCTTGAG	TCCAACCCGG	TAAGACACGA	CTTATCGCCA	CTGGCAGCAG
2770	2780	2790	2800	2810	2820
CCACTGGTAA	CAGGATTAGC	AGAGCGAGGT	ATGTAGGCGG	TGCTACAGAG	TTCTTGAAGT
2830	2840	2850	2860	2870	2880
GGTGGCCTAA	CTACGGCTAC	ACTAGAAGGA	CAGTATTTGG	TATCTGCGCT	CTGCTGAAGC
2890	2900	2910	2920	2930	2940
CAGTTACCTT	CGGAAAAAGA	GTTGGTAGCT	CTTGATCCGG	CAAACAAACC	ACCGCTGGTA
2950	2960	2970	2980	2990	3000
GCGGTGGTTT	TTTTGTTTGC	AAGCAGCAGA	TTACGCGCAG	AAAAAAGGA	TCTCAAGAAG
3010	3020	3030	3040	3050	3060
ATCCTTTGAT	CTTTTCTACG	GGGTCTGACG	CTCAGTGGAA	CGAAAACTCA	CGTTAAGGGA
3070	3080	3090	3100	3110	3120
TTTTGGTCAT	GAGATTATCA	AAAAGGATCT	TCACCTAGAT	CCTTTTAAAT	TAAAAATGAA
3130	3140	3150	3160	3170	3180
GTTTTAAATC	AATCTAAAGT	ATATATGAGT	AAACTTGGTC	TGACAGTTAC	CAATGCTTAA
3190	3200	3210	3220	3230	3240
TCAGTGAGGC	ACCTATCTCA	GCGATCTGTC	TATTTCTGTC	ATCCATAGTT	GCCTGACTCC
3250	3260	3270	3280	3290	3300
CCGTCGTGTA	GATAACTACG	ATACGGGAGG	GCTTACCATC	TGGCCCCAGT	GCTGCAATGA
3310	3320	3330	3340	3350	3360
TACCGCGAGA	CCCACGCTCA	CCGGCTCCAG	ATTTATCAGC	AATAAACCAG	CCAGCCGGAA
3370	3380	3390	3400	3410	3420
GGGCCGAGCG	CAGAAGTGGT	CCTGCAACTT	TATCCGCCTC	CATCCAGTCT	ATTAATTGTT
3430	3440	3450	3460	3470	3480
GCCGGGAAGC	TAGAGTAAGT	AGTTCGCCAG	TTAATAGTTT	GCGCAACGTT	GTTGCCATTG
3490	3500	3510	3520	3530	3540
CTACAGGCAT	CGTGGTGTCA	CGCTCGTCGT	TTGGTATGGC	TTCATTACAG	TCCGGTTCCC

Figure 2 (cont)

3550	3560	3570	3580	3590	3600
AACGATCAAG	GCGAGTTACA	TGATCCCCCA	TGTTGTGCAA	AAAAGCGGTT	AGTCCCTTCG
3610	3620	3630	3640	3650	3660
GTCCTCCGAT	CGTTGTCAGA	AGTAAGTTGG	CCGCAGTGTT	ATCACTCATG	GTTATGGCAG
3670	3680	3690	3700	3710	3720
CACTGCATAA	TTCTCTTACT	GTCATGCCAT	CCGTAAGATG	CTTTTCTGTG	ACTGGTGAGT
3730	3740	3750	3760	3770	3780
ACTCAACCAA	GTCATTCTGA	GAATAGTGTA	TGCGGCGACC	GAGTTGCTCT	TGCCCCGCGT
3790	3800	3810	3820	3830	3840
CAATACGGGA	TAATACCGCG	CCACATAGCA	GAACTTTAAA	AGTGCTCATC	ATTGGAAAAC
3850	3860	3870	3880	3890	3900
GTTCTTCGGG	GCGAAACTC	TCAAGGATCT	TACCGCTGTT	GAGATCCAGT	TCGATGTAAC
3910	3920	3930	3940	3950	3960
CCACTCGTGC	ACCCAAGTGA	TCTTCAGCAT	CTTTTACTTT	CACCAGCGTT	CATGAGCAAA
3970	3980	3990	4000	4010	4020
AACAGGAAGG	CAAAATGCCG	CAAAAAGGG	AATAAGGGCG	ACACGGAAAT	GTTGAATACT
4030	4040	4050	4060	4070	4080
CATACTCTTC	CTTTTCAAT	ATTATTGAAG	CATTTATCAG	GTTATTGTG	TCATGAGCGG
4090	4100	4110	4120	4130	4140
ATACATATTT	GAATGTATTT	AGAAAAATAA	ACAAATAGGG	GTTCCGCGCA	CATTTCCCCG
4150	4160	4170	4180	4190	4200
AAAAGTGCCA	CCTGACGTCT	AAGAAACCAT	TATTATCATG	ACATTAACT	ATAAAAATAG
4210	4220	4230	4240	4250	4260
GCGTATCAG	AGGCCCTTTC	GTCTCGCGG	TTTCGGTGAT	GACGGTGAAA	ACCTCTGA
4270	4280	4290	4300	4310	4320
CATGCAGCTC	CCGGAGACGG	TCACAGCTTG	TCTGTAAGCG	GATGCCGGGA	GCAGACAAGC
4330	4340	4350	4360	4370	4380
CCGTCAGGGC	GCGTCAGCGG	GTGTTGGCGG	GTGTCGGGGC	TGGCTTAAC	ATGCGGCATC
4390	4400	4410	4420	4430	4440
AGAGCAGATT	GTAAGTGAAG	TGCACCATAT	GCGGTGTGAA	TCTCGTACGC	ACGTGCCCTCA
4450	4460	4470	4480	4490	4500
GTACGTAAGA	GGTTCCAAC	TTCACCATAA	TGAAATAAGA	TCACTACCGG	GCGTATTTTT
4510	4520	4530	4540	4550	4560
TGAGTTATCG	AGATTTTCAG	GAGCTAAGGA	AGCTAAATG	GAGAAAAAA	TCACTGGATA
4570	4580	4590	4600	4610	4620
TACCACCGTT	GATATATCCC	AATGGCATCG	TAAAGAACAT	TTTGAGGCAT	TTCAGTCAGT
4630	4640	4650	4660	4670	4680
TGCTCAATGT	ACCTATAACC	AGACCGTTCA	ACTGGATATT	ACGGCCTTTT	TAAAGACCGT
4690	4700	4710	4720	4730	4740
AAAGAAAAAT	AAGCACAAGT	TTTATCCGGC	CTTTATTAC	ATTCTTGCCC	GCCTGATGAA

Figure 2 (cont)


4750	4760	4770	4780	4790	4800
TGCTCATCCC	GAGTTCCGTA	TGGCAATGAA	AGACGGTGAG	CTGGTGATAT	GGGATAGTGT
4810	4820	4830	4840	4850	4860
TCACCCCTTGT	TACACCGTTT	TCCATGAGCA	AACTGAAACG	TTTTCATCGC	TCTGGAGTGA
4870	4880	4890	4900	4910	4920
ATACCACGAC	GATTTCCGGC	AGTTTCTACA	CATATATTCT	CAAGATGTGG	CGTGTTCACG
4930	4940	4950	4960	4970	4980
TGAAAACCTG	GCCTATTTCC	CTAAAGGGTT	TATTGAGAAT	ATGTTTTTTC	TCTCAGCCAA
4990	5000	5010	5020	5030	5040
TCCCTGGGTG	AGTTTCACCA	GTTTTGATTT	AAACGTGGCC	AATATGGACA	ACTTCTTCGC
5050	5060	5070	5080	5090	5100
CCCCGTTTTT	ACAATGGGCA	AATATTATAC	GCAAGGCGAC	AAGGTGCTGA	TGCCGCTGGC
5110	5120	5130	5140	5150	5160
GATTTCAGGT	CATCATGCCG	TTTGTGATGG	CTTCCATGTC	GGCAGAATGC	TTAATGAATT
5170	5180	5190	5200	5210	5220
ACAACAGTGT	ACCGCATCAG	GCGAAATTGT	AAACGTTAAT	ATTTTGTAA	AATTCGCGTA
5230	5240	5250	5260	5270	5280
AATATTTGTT	AAATCAGCTC	ATTTTTTAAC	CAATAGGCCG	AAATCGGCAA	AATCCCTTAT
5290	5300	5310	5320	5330	5340
AAATCAAAAG	AATAGACCGA	GATAGGGTTG	AGTGTGTGTC	CAGTTTGGAA	CAAGAGTCCA
5350	5360	5370	5380	5390	5400
CTATTAAAGA	ACGTGGACTC	CAACGTCAAA	GGGCGAAAAA	CCGTCTATCA	GGGCGATGGC
5410	5420	5430	5440	5450	5460
CCACTACGTG	AACCATCACC	CAAATCAAGT	TTTTTGCGGT	CGAGGTGCCG	TAAAGCTCTA
5470	5480	5490	5500	5510	5520
AATCGGAACC	CTAAAGGGAG	CCCCGATTTT	AGAGCTTGAC	GGGGAAGGCC	GGCGAACGTG
5530	5540	5550	5560	5570	5580
GCGAGAAAGG	AAGGGAAGAA	AGCGAAAGGA	GCGGGCGCTA	GGGCGCTGGC	AAGTGTAGCG
5590	5600	5610	5620	5630	5640
GTCACGCTGC	GCGTAACCAC	CACACCCGCC	GCGCTTAATG	CGCCGCTACA	GGGCGCGTCC
5650	5660	5670	5680	5690	5700
ATTGCGCATT	CAGGCTGCGC	AACTGTTGGG	AAGGGCGATC	GGTGCGGGCC	TCTTCGCTAT
5710	5720	5730	5740	5750	5760
TACGCCAGCC	CAAGCTACCA	TGATAAGTAA	GTAATATTAA	GGTACGGGAG	GTACTTGGAG
5770	5780	5790	5800	5810	5820
CGGCCGCAAT	AAAATATCTT	TATTTTCATT	ACATCTGTGT	GTTGGTTTTT	TGTGTGAATC
5830	5840	5850	5860	5870	5880
GATAGTACTA	ACATACGCTC	TCCATCAAAA	CAAAACGAAA	CAAAACAAAC	TAGCAAAATA
5890	5900	5910	5920	5928	
GGCTGTCCCC	AGTGCAAGTG	CAGGTGCCAG	AACATTCTCT	TATCGATA	(SEQ ID NO:25)

Figure 2 (cont)

annotations:

START	END	DIRECTION	DESCRIPTION
-----	---	-----	-----
38	295	->	Telomerase Minimal Promoter.
295	310	->	EcoRI site and Kozak Sequence.
308	1864	->	Secreted Alkaline Phosphatase Gene.
1860	2080	->	Late Poly-A addition site of SV40.
2394	2976	->	Bacterial Origin of Replication.
3170	4023	<-	Ampillicin Resistance Gene Made Sensitive by Mutagenesis.
4538	5196	->	Chloramphenicol Resistance Gene.
5217	5401	<-	F1 Origin of Replication.
5768	5921	->	Transcription blocker.

Figure 3



SEQUENCE LISTING

<110> Sierra Sciences, Inc.

<120> METHODS AND COMPOSITIONS FOR MODULATING
TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION

<130> SIER-005WO

<150> 60/227,865

<151> 2000-08-24

<150> 60/230,174

<151> 2000-09-01

<150> 60/238,345

<151> 2000-10-05

<160> 25

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 41

<212> DNA

<213> human

<400> 1

ggccccgccc tctcctcgcg ggcgcgagttt caggcagcgc t 41

<210> 2

<211> 13

<212> DNA

<213> human

<400> 2

ggcgcgagtt tca 13

<210> 3

<211> 10

<212> DNA

<213> human

<400> 3

cgcgagtttc 10

<210> 4

<211> 21

<212> DNA

<213> human

<400> 4

ggcgcgagtt tcaggcagcg c 21

<210> 5

<211> 85

<212> PRT

<213> human

<400> 5

Gly Arg Gly Arg His Pro Gly Lys Gly Val Lys Ser Pro Gly Glu Lys
1 5 10 15

Ser Arg Tyr Glu Thr Ser Leu Asn Leu Thr Thr Lys Arg Phe Leu Glu
 20 25 30
 Leu Leu Ser His Ser Ala Asp Gly Val Val Asp Leu Asn Trp Ala Ala
 35 40 45
 Glu Val Leu Lys Val Gln Lys Arg Arg Ile Tyr Asp Ile Thr Asn Val
 50 55 60
 Leu Glu Gly Ile Gln Leu Ile Ala Lys Lys Ser Lys Asn His Ile Gln
 65 70 75 80
 Trp Leu Gly Ser His
 85

<210> 6
 <211> 76
 <212> PRT
 <213> human

<400> 6
 Pro Pro Gly Thr Pro Ser Arg His Glu Lys Ser Leu Gly Leu Leu Thr
 1 5 10 15
 Thr Lys Phe Val Ser Leu Leu Gln Glu Ala Lys Asp Gly Val Leu Asp
 20 25 30
 Leu Lys Leu Ala Ala Asp Thr Leu Ala Val Arg Gln Lys Arg Arg Ile
 35 40 45
 Tyr Asp Ile Thr Asn Val Leu Glu Gly Ile Gly Leu Ile Glu Lys Lys
 50 55 60
 Ser Lys Asn Ser Ile Gln Trp Lys Gly Val Gly Pro
 65 70 75

<210> 7
 <211> 78
 <212> DNA
 <213> human

<400> 7
 ctcctcgagg cgcgagtttc aggcagcgct gcgtcctgct gcgcacgtgg gaagccctgg 60
 ccccgccac ccccgcca 78

<210> 8
 <211> 10
 <212> DNA
 <213> human

<400> 8
 cgcgagtttc 10

<210> 9
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> synthetic oligonucleotide

<400> 9
 tctcctcgcg gcgcgagttt cagg 24

<210> 10
 <211> 26
 <212> DNA
 <213> Artificial Sequence

<220>

<223> synthetic oligonucleotide
 <400> 10
 tctcctcgcg gcgcgagttt caggca 26
 <210> 11
 <211> 28
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> synthetic oligonucleotide
 <400> 11
 tctcctcgcg gcgcgagttt caggcagc 28
 <210> 12
 <211> 29
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> synthetic oligonucleotide
 <400> 12
 tctcctcgcg gcgcgagttt caggcagcg 29
 <210> 13
 <211> 30
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> synthetic oligonucleotide
 <400> 13
 tctcctcgcg gcgcgagttt caggcagcgc 30
 <210> 14
 <211> 28
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> synthetic oligonucleotide
 <400> 14
 ctcgcggcgc gagtttcagg cagcgctg 28
 <210> 15
 <211> 30
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> synthetic oligonucleotide
 <400> 15
 tctcctcgcg gcgcgagttt caggcagcgc 30
 <210> 16
 <211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 16
tcctcgcggc gcgagtttca ggcagcgc 28

<210> 17
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 17
ctcgcggcgc gagtttcagg cagcgc 26

<210> 18
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 18
cgcggcgcca gtttcaggca gcgctgcgc 30

<210> 19
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 19
cggcgcgagt ttcaggcagc gctgcgc 28

<210> 20
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 20
gcgcgagttt caggcagcgc tgcgc 26

<210> 21
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> synthetic oligonucleotide

<400> 21
cgcgagtttc aggcagcgcgc gcgc 25

<210> 22
<211> 24
<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide

<400> 22

gcgagtttca ggcagcgctg cgtc

24

<210> 23

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide

<400> 23

tctcctcgcg gcgagagttt caggcagcgc

30

<210> 24

<211> 261

<212> DNA

<213> human

<400> 24

ccaggaccgc gctccccacg tggcggaggg actggggacc cgggcacccg tcctgcccct 60
 tcaccttcca gctccgcctc ctccgcgcgg accccgcccc gtcccgaccc ctcccgggtc 120
 cccggcccag cccctccgg gccctccag cccctccct tcctttccgc ggccccgccc 180
 tctcctcgcg gcgagagttt caggcagcgc tgcgtcctgc tgcgcacgtg ggaagccctg 240
 gccccggcca cccccgat g 261

<210> 25

<211> 5928

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic expression plasmid

<400> 25

ggtaccgagc tcttacgctg gctagcccgg gctcgagcca ggaccgcgct cccacagtgg 60
 cggagggaact ggggaccogg gcaccogtcc tgccccttca ccttccagct cgcctcctc 120
 cgcgoggacc ccgcccogtc ccgaccctcc ccgggtcccc ggcccagccc cctccgggcc 180
 ctcccagccc ctccccttcc ttcccgcggc ccgcctctct cctcgoggcg cgagtctcag 240
 gcagcgctgc gtccgtctgc gcacgtggga agccctggcc ccggccaccc ccgcgaattc 300
 gcccacatgc ctgctgctgc tgctgctgct gggcctgagg ctacagctct ccctgggcat 360
 catcccagtt gaggaggaga acccggactt ctggaaccgc gaggcagccg aggccttggg 420
 tgccgccaag aagctgcagc ctgcacagac agccgccaag aacctcatca tcttcttggg 480
 cgatgggatg ggggtgtcta cgggtgacgc tgccaggatc ctaaaagggc agaagaagga 540
 caaactgggg cctgagatac ccctggccat ggaccgcttc ccatatgttg ctctgtccaa 600
 gacatacaat gtagacaaac atgtgccaga cagtggagcc acagccacgg cctacctgtg 660
 cggggtcaag ggcaacttcc agaccattgg cttgagtga gccgcccgt ttaaccagtg 720
 caacacgaca cgcggcaacg aggtcatctc cgtgatgaat cgggccaaga aagcagggaa 780
 gtcagtggga gtggtaaoca ccacacgagt gcagcacgcc tcgccagccg gcacctacgc 840
 ccacacgggt aaccgcaact ggtactcgga cgcgcagctg cctgcctcgg ccgcccagga 900
 ggggtgccag gacatcgcta cgcagctcat ctccaacatg gacattgacg tgatccctagg 960
 tggaggccga aagtacatgt ttcgcatggg aaccccagac cctgagtacc cagatgacta 1020
 cagccaaggt gggaccaggc tggacgggaa gaatctgggt caggaatggc tggcgaagcg 1080
 ccagggtgcc cggtatgtgt ggaaccgcac tgagctcatg caggcttccc tggaccctgc 1140
 tgtgacctat ctcatgggtc tctttgagcc tggagacatg aaatacgaga tccaccgaga 1200
 ctccacactg gacccctccc tgatggagat gacagaggct gccctgcgcc tgcagagcag 1260
 gaacccccgc ggcttcttcc tcttcgtgga ggggtggtgc atcgaccatg gtcacatga 1320
 aagcagggtc taccgggcac tgactgagac gatcatgttc gacgacgcca ttgagagggc 1380
 gggccagctc accagcgagg aggcacgcct gaggctcgtc actgccgacc actcccacgt 1440

cttctccttc	ggaggetacc	ccctgcgagg	gagctccatc	ttcgggctgg	cccctggcaa	1500
ggcccgggac	aggaaggcct	acacgggtcct	cctatacgga	aacgggtccag	gctatgtgct	1560
caaggacggc	gcccggcccg	atgttaccca	gagcgagagc	gggagccccc	agtatcgcca	1620
gcagtcagca	gtgcccctgg	acgaagagac	ccacgcaggc	gaggacgtgg	cggtgttcgc	1680
gcgcggcccg	caggcgcaacc	tgggttcacgg	cgtgcaggag	cagaccttca	tagcgcacgt	1740
catggccttc	gccgcctgcc	tggagcccta	caccgcctgc	gacctggcgc	ccccgcggcg	1800
caccaccgac	gccgcgcacc	cggtttactc	tagagtccgg	gcggccggcc	gcttcgagca	1860
gacatgataa	gatacattga	tgagtttggg	caaaccacaa	ctagaatgca	gtgaaaaaaa	1920
tgctttatct	gtgaaatttg	tgatgctatt	gctttatctg	taaccattat	aagctgcaat	1980
aaacaagtta	acaacaacaa	ttgcattcat	tttatgtttc	aggttcaggg	ggaggtgtgg	2040
gaggtttttt	aaagcaagta	aaacctctac	aaatgtggta	aaatcgataa	ggatccgtcg	2100
accgatgcoc	ttgagagcct	toaaccagct	cagctccttc	cggtgggcgc	ggggcatgac	2160
tatcgtcgcc	gcacttatga	ctgtcttctt	tatcatgcaa	ctcgtaggac	aggtgccggc	2220
agcgtctctc	cgcttcctcg	ctcactgact	cgctgcgctc	ggtcgttcgg	ctgcggcgag	2280
cggtatcagc	tactctaaag	goggtaatat	ggttatccac	agaatcaggg	gataacgcag	2340
gaaagaacat	gtgagcaaaa	ggccagcaaa	aggccaggaa	ccgtaaaaag	gccgcgttgc	2400
tgcggttttt	ccataggctc	cgccccctgc	acgagcatca	caaaaatoga	cgctcaagtc	2460
agagtgggcg	aaacccgaca	ggactataaa	gataccaggc	gtttccccct	ggaagctccc	2520
tcgtgcgctc	tcctgttccg	accctgccgc	ttaccggata	cctgtccgcc	tttctccctt	2580
cggaagcgt	ggcgctttct	catagctcac	gctgtaggta	tctcagttcg	gtgtaggtcg	2640
ttcgctccaa	gctgggctgt	gtgcacgaac	cccccgttca	gcccgaccgc	tgcgcttat	2700
ccggttaacta	tcgtcttgag	tcacaaccgg	taagacacga	cttatcgcca	ctggcagcag	2760
ccactggtaa	caggattagc	agagcgaggt	atctaggcgg	tgctacagag	ttcttgaggt	2820
ggtggcctaa	ctacggctac	actagaagga	cagtatttgg	tatctgcgct	ctgctgaagc	2880
cagttacott	cggaaaaaa	gttggttagct	cttgatccgg	caaaacaaac	accgctggtg	2940
gcgttggttt	ttttgtttgc	aagcagcaga	ttacgcgcag	aaaaaaagga	tctcaagaag	3000
atcctttgat	cttttctacg	gggtctgacg	ctcagtgga	cgaaaactca	cgtaaaggga	3060
ttttggtcat	gagattatca	aaaaggatct	tcacctagat	ccttttaaat	taaaaatgaa	3120
gttttaaatc	aatctaaagt	atatatgagt	aaacttggtc	tgacagttac	caatgcttaa	3180
tcagtggagg	acctatctca	gogatctgtc	tatttcgttc	atccatagtt	gcctgactcc	3240
ccgtcgtgta	gataactacg	atacgggagg	gcttaccatc	tgccccaggt	gctgcaatga	3300
taccgcgaga	cccacgctca	ccggctccag	atttatcagc	aataaaaccag	ccagccggaa	3360
ggcccgagcg	cagaagtggg	cctgcaactt	tatccgcctc	catccagttc	attaattggt	3420
gccgggaagc	tagagtaagt	agttcgccag	ttaatatggt	gcgcaacggt	ggtgccattg	3480
ctacaggcat	cgtggtgtca	cgctcgtcgt	ttggtatggc	ttcattcagc	tccggttccc	3540
aacgatcaag	gcgagttaca	tgatccccca	tgttgtgcaa	aaaagcgggt	agctccttcg	3600
gtcctccgat	cgttgtcaga	agtaagttgg	ccgcagtggt	atcactcatg	gttatggcag	3660
cactgcataa	ttctcttact	gtcatgccat	ccgtaagatg	cttttctgtg	actggtgagt	3720
actcaacca	gaattcttga	gaatagtgtg	tgccgcgacc	gagtgtctct	tgcccgcgct	3780
caatacggga	taataccgcg	ccacatagca	gaactttaaa	agtgtctatc	attggaaaac	3840
gttcttcggg	gcgaaaactc	tcaaggatct	taccgctggt	gagatccagt	tcgatgtaac	3900
ccactcgtgc	acccaactga	tcttcagcat	cttttacttt	caccagcggt	catgagcaaa	3960
aacaggaagg	caaaatgccg	caaaaaaggg	aataaggggc	acacggaaa	gttgaatact	4020
catactcttc	ctttttcaat	attattgaag	catttatcag	ggttattgtc	tcgatgacgg	4080
atacatatct	gaatgtatct	agaaaaataa	acaaaatagg	gttccgcgca	catttccccg	4140
aaaagtgcc	cctgacgtct	aagaaacat	tatttatcatg	acattaaact	ataaaaaatg	4200
gcgtatcaag	aggccctttc	gtctcgcgcg	ttcgggtgat	gacggtgaaa	acctctgaca	4260
catgcagctc	ccggagacgg	tcacagcttg	tctgtaagcg	gatgccggga	gcagacaagc	4320
ccgtcagggc	gcgtcagcgg	gtgttgccgg	gtgtcggggc	tggttaact	atgcggcatc	4380
agagcagatt	gtactgagag	tgacccatat	gcggtgtgaa	tctcgtacgc	acgtgcctca	4440
gtacgtaaga	ggttccaact	ttcaccataa	tgaataaaga	tcactaccgg	gcgtattttt	4500
tgagttatcg	agattttcag	gagctaagga	agctaaaatg	gagaaaaaaa	tcactggata	4560
taccaccggt	gatataatcc	aatggcatcg	taaagaacat	tttgaggcat	ttcagtcagt	4620
tgctcaatgt	acctataa	agaccgttca	actggatatt	acggcctttt	taaagaccgt	4680
aaagaaaaat	aagcacagt	tttatccggc	ctttattcac	attcttgccc	gcctgatgaa	4740
tgctcatccc	gagttccgta	tggcaatgaa	agacgggtgag	ctggtgata	gggtagtgt	4800
tcacccttgt	tacaccgttt	tccatgagca	aactgaaacg	ttttcatcgc	tctggagtga	4860
ataccacgac	gatttccggc	agttttctaca	catatattcg	caagatgtgg	cgtgttacgg	4920
tgaaaaacct	gcctatttcc	ctaaagggtt	tattgagaat	atgtttttcg	tctcagccaa	4980
tccttggttg	agttttacca	gttttgattt	aaaogtggcc	aatatggaca	acttcttcgc	5040
ccccgttttc	acaatgggca	aatattatgc	gcaaggcgac	aaggtgctga	tgccgctggc	5100
gattcaggtt	catcatgccg	tttgtgatgg	cttccatgtc	ggcagaatgc	ttaatgaatt	5160
acaaacagtg	accgcacag	gogaaattgt	aaacgttaat	attttgttaa	aattcgcgta	5220
aatatttgtt	aaatcagctc	attttttaac	caataggccg	aaatcggcaa	aatcccttat	5280

aaatcaaaaag	aatagaccga	gataggggtg	agtgttggtc	cagtttgga	caagagtcca	5340
ctattaaaaga	acgtggactc	caacgtcaaa	gggcgaaaaa	ccgtctatca	gggcgatggc	5400
ccactacgtg	aaccatcacc	caaatacaagt	tttttgcggt	cgaggtgccg	taaagctcta	5460
aatcggaacc	ctaaaggag	ccccgatatt	agagcttgac	ggggaagcc	ggcgaacgtg	5520
gcgagaaaag	aaggaagaa	agcgaaagga	gcggcgcta	gggcgctggc	aagtgtagcg	5580
gtcacgctgc	gcgtaaccac	cacacccgcc	gcgcttaatg	cgccgctaca	gggcgcgtcc	5640
attcgccatt	caggctgcgc	aactgttggg	aaggcgatc	ggtgcgggcc	tcttcgctat	5700
tacgccagcc	caagctacca	tgataagtaa	gtaatatata	ggtacgggag	gtacttgag	5760
cgccgcaat	aaaatatctt	tattttcatt	acatctgtgt	gttggttttt	tgtgtgaatc	5820
gatagtacta	acatacgctc	tccatcaaaa	caaacgaaa	caaaacaaac	tagcaaaaata	5880
ggctgtcccc	agtgaagtg	cagggtgccag	aacatttctc	tatcgata		5928

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/25861

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12Q 3/00, 1/68, 33/567; C12P 21/04; C12N 15/00, 5/00; C07H 21/04

US CL : 435/3, 6, 7.21, 320.1, 325; 514/44; 424/93.1; 536/24.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/3, 6, 7.21, 320.1, 325; 514/44; 424/93.1; 536/24.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, CAPLUS, USPATFUL, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HORRKAUWA I. et al. Cloning and characterization of the promoter region of human telomerase. Cancer Research, February 15, 1999. Vol. 59, pages 826-830. See the entire document.	1-22
A	WICK M et al. Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene 1999. Vol. 232, pages 97-106. See the entire document.	1-22
A	CROWE DL et al. E2F represses transcription of the human telomerase reverse transcriptase gene. Nucleic Acid Research 2001. Vol. 29, pages 2789-2794. See the entire document.	1-22

☐ Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"Z" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

07 November 2001 (07.11.2001)

Date of mailing of the international search report

28 DEC 2001

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks

Box PCT

Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer:

Ram R. Shukla

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/25861

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-22

Remark on Protest

☐
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/25861

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-22, drawn to a method of enhancing expression of TERT in an expression system comprising a Site C repressor binding site in vivo and ex vivo.

Group II, claim(s) 23-33, drawn to a method of decreasing telomerase expression in a cell ex vivo and in vivo.

Group III, claim(s) 34-41, drawn to a nucleic acid comprising a nucleotide sequence that is same or identical to a Site C repressor binding site.

Group IV, claim(s) 42-45, drawn to a double stranded DNA decoy sequence comprising a Site C repressor binding site.

Group V, claim(s) 46-49, drawn to a method of screening for agents that inhibit a Site C repressor binding site mediated repression of TERT transcription.

Group VI, claim(s) 50 and 51, drawn to a mammalian cell comprising a telomerase gene that comprises a deletion of a Site C repressor binding site.

Group VII, claim(s) 52, drawn to a method of producing a mammalian antibody.

The inventions listed as Groups I-VII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The invention of group I requires an agent that enhances TERT expression whereas the method of group II requires an agent that inhibits TERT expression. Therefore the inventions of groups I and II lack the same special technical feature.

The invention of group III is a nucleic acid sequence that is identical to a Site C repressor binding site and would include nucleic acid sequences that would not function as a Site C repressor binding site and therefore, it lacks the same technical feature as groups I and II.

The invention of group IV is a double stranded decoy which is not required for the methods of groups I-II and therefore, lacks the same technical feature as that of groups I-II. Furthermore, its structure is distinct from that of the nucleic acid of group III.

The invention of group V lacks the same special technical feature because the steps of groups I-III can not be used to practice this method and this method can be used for making the compositions of groups III and IV.

The invention of group VI is drawn to a mammalian cell that can not be made by the methods of the groups I-II and V and its structure is distinct from that of the the compositions of groups III and IV.

The invention of group VII is for producing an antibody and its steps can be used for practicing the methods of groups I and II or vice versa. Furthermore, the compositions of groups III, IV, and V can not be used in this method.